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ABSTRACT OF THE DISSERTATION 
Automating Intensity Modulated Radiation Therapy Treatment Planning by using Hierarchical 
Optimization  
by 
Paras Babu Tiwari 
Doctor of Philosophy in Computer Science 
Washington University in St. Louis, 2015 
Professor Yixin Chen, Chair 
The intensity modulated radiation therapy (IMRT) optimizes the beam’s intensity to deliver the 
prescribed dose to the target while minimizing the radiation exposure to normal structures. The 
IMRT optimization is a complex optimization problem because of the multiple conflicting 
objectives in it. Due to the complexity of the optimization, the IMRT treatment planning is still a 
trial and error process. Hierarchical optimization was proposed to automate the treatment 
planning process, but its potential has not been demonstrated in a clinical setting. Moreover, 
hierarchical optimization is slower than the traditional optimization. The dissertation studied a 
sampling algorithm to reduce the hierarchical optimization time, customized an open source 
optimization solver to solve the nonlinear optimization formulation and demonstrated the 
potential of hierarchical optimization to automate the treatment planning process in a clinical 
setting. We generated the treatment plans of 31 prostate patients by hierarchical optimization 
using the same criteria as used by planners to prepare the treatment plans at Memorial Sloan 
Kettering Cancer Center. We found that hierarchical optimization produced the same or better 
treatment plans than that produced by a planner using the Eclipse treatment planning system. 
Therefore, the dissertation demonstrated that hierarchical optimization could automate the 
xvii 
 
treatment planning process and shift the paradigm of the treatment planning from manual trial 
and error to an ideal automated process. 
 
1 
 
Chapter 1:  Introduction 
Intensity-modulated radiation therapy (IMRT) is widely used to deliver radiation therapy [1]–[3]. 
The IMRT optimization has multiple conflicting goals, and it requires substantial time and trial 
and error iterations to find an acceptable treatment plan. The most important goal is to deliver the 
prescribed dose to target structures and then to minimize dose to normal organs. To reflect the 
importance of a goal in the optimization, a weight is assigned to each goal. The planner chooses 
these weights based on experience and runs the treatment planning application to find a preferred 
dose distribution. Often, it is difficult to find a set of weights that result in a good dose 
distribution. Therefore, the optimization is run several times and the weight parameters are 
tweaked to find an acceptable treatment plan.  
There has been substantial research in automating the treatment planning process using 
hierarchical optimization [4]–[6]. Hierarchical optimization assigns priorities to goals of the 
optimization and optimizes those goals based on priority. The purpose of prioritization is to 
ensure that the higher priority goals are not sacrificed to improve on the lower priority goals. 
Wilkens and Clark, et al.[4], [7] demonstrated the potential of hierarchical optimization by 
automatically creating treatment plans for head and neck and prostate plans. However, the 
treatment plan automation based on hierarchical optimization has not been extensively studied in 
a clinical setting. The clinical setting has complex beam arrangements, finer beam resolutions 
and rigorous dose distribution requirements. Therefore, it is essential to demonstrate that 
hierarchical optimization could generate the clinically acceptable plans before drawing any 
conclusions. Moreover, hierarchical optimization is slower than traditional optimization because 
hierarchical optimization increases the problem size. 
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The dissertation addresses three needs in the treatment planning optimization: 1) we explored the 
sampling method to reduce the hierarchical optimization time, 2) we customized Interior Point 
Optimizer, an open source solver that can solve general nonlinear function, to solve the 
hierarchical optimization problem[1], 3) we formulated the mathematical model to automate the 
treatment planning process in the clinical setting and automatically prepared the treatment plans 
of 31 prostate patients using the formulated mathematical model. The present study, therefore, 
demonstrated the potential of hierarchical optimization to shift the treatment planning paradigm 
from manual trial and error to an ideal automated process. 
1.1 Background 
The history of radiation therapy can be traced back to 1895 when Wilhelm Conrad Röntgen 
discovered the X-ray [2]. The discovery of the X-ray led to widespread use of radiation in 
diagnosis and treatment in the medical field. Emil Grubbe, a medical student from Chicago, 
experimented with X-rays as treatment for breast cancer in 1896 [3]. Grubbe’s treatment greatly 
benefited patients and radiation therapy was widely used to treat cancer patients in the US and 
Europe.  
Although X-rays gained widespread popularity, there were several challenges in using them to 
treat cancer. The first challenge is that the X-ray kills both tumor and normal cells. There was 
limited knowledge about the impact of X-rays on normal cells. The limited knowledge about X-
rays led to a high patient mortality rate. Later, it was realized that radiation was better tolerated if 
administered in small amounts over a long period. This idea is called fractionation and was 
primarily due to Prof. Claude Regaud from the Paris Institute. The second challenge was that the 
X-rays of that era had low energy[4]. The energy of X-rays was in the range of 180-200KV and 
such low energy X-rays were not powerful enough to treat tumors situated deep inside tissue. 
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The subsequent research led to the development of the machine that could produce super voltage 
X-rays. William David Coolidge built the first supervoltage X-rays machine that could produce 
an X-ray of approximately 500kV-2MV energy in 1927[5].  
The scientific advancement led to the development of the megavoltage linear accelerator[6], [7]. 
The Varian Medical System began to build the first commercial linear accelerator in 1958. 
Figure 1-1 shows the modern linear accelerator built by Varian Medical Systems. The modern 
linear accelerator uses microwave technology that can produce high energy X-rays of 6-18 MV. 
The electrons produced by the electron gun are accelerated through the waveguide. The 
accelerated electrons collide with the heavy metallic target to produce a high energy X-ray. 
Finally, the X-ray particle is reshaped using the multi-leaf collimator to produce the dose 
distribution that matches the patient geometry[8].  
In recent years, there has been substantial research on producing dose distribution that conforms 
to patient geometry[9]–[14]. The linear accelerator is equipped with multi-leaf collimators that 
can shape the radiation to match patient geometry[15]. The multi-leaf collimator consists of the 
individual leaves that can be opened and closed to produce the desired dose distribution (Figure 
1-2). The multi-leaf collimator is controlled by the treatment planning application, which uses 
mathematical optimization to determine the leaves’ position. The research on developing the 
treatment planning application that can automatically produce conformal dose distribution is still 
an active research area.  
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Figure 1-1 The modern linear accelerator developed by Varian Medical Systems. The modern linear 
accelerator can produce an X-ray of 6-18MV [16].  
 
Figure 1-2 The multi-leaf collimator of the modern linear accelerator. The multi-leaf collimator shapes 
the radiation to produce the dose distribution that matches with patient geometry [16]. 
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1.1.1 Conformal Radiation Therapy 
The conformal radiation therapy is a type of external radiation therapy that uses advanced 
technology to produce the dose distribution that conforms to patient geometry[17]. The research 
in medical physics and computer science has advanced imaging [18], planning[19] and delivery 
technologies[20]. Modern imaging technology can generate the three-dimensional image of the 
patient. The three-dimensional image provides accurate information about the location, size, and 
shape of the target and normal structures[18], [21]–[25]. Planning technology has advanced as a 
result of imaging technology advancement. The treatment planning application can calculate the 
accurate dose to structures, visualize the dose distribution, and perform optimization due to the 
geometrical information obtained from the three-dimensional image of the patient[26]–[29]. The 
planner can produce conformal dose distribution using the modern treatment planning 
application. Finally, the delivery techniques have also advanced as a result of imaging and 
planning  technology advancement[30]. Modern linear accelerators are equipped with multi-leaf 
collimators that can shape the radiation to match patient geometry.  
 Three-dimensional conformal radiation therapy (3DCRT) was the first attempt to produce 
conformal dose distribution. In 3DCRT, the three-dimensional image of the patient is generated 
using the CT/PET scanner. The images produced from the scanner are imported into the 
treatment planning application. The treatment planning application provides the functionalities 
such as contouring the structures, discretizing the structure into voxels, calculating dose to each 
voxel of the structures, and navigating to the different slices of images. The patient geometry can 
be visualized to the physician using the treatment planning application. The physician chooses 
the beam direction that delivers the prescribed dose to the target and minimizes the radiation 
exposure to normal structures. The planner inputs the chosen beam direction in the treatment 
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planning application and calculates the dose to each structure. The physician provides the 
feedback to the plan prepared by the planner, and the planner modifies the plan based on 
physician feedback. The process is repeated until the desired dose distribution is found. 
 
Figure 1-3 The 3DCRT vs. IMRT dose distribution. The 3DCRT uses beams of uniform intensity, while 
IMRT uses beams of variable intensity for treatment. Therefore, the dose distribution produced in IMRT 
better conforms to the target structure than that produced in 3DCRT [31]. 
 
Although 3DCRT improved the quality of radiation therapy, it still has limitations. The 3DCRT 
uses the uniform intensity beam for treatment. The uniform intensity beam produces the uniform 
dose around the target. Therefore, the 3DCRT cannot spare the normal structures located near the 
target structure (Figure 1-3). Intensity modulated radiation therapy is the advanced form of the 
three-dimensional conformal radiation therapy[32]. Unlike 3DCRT, the intensity of each beam 
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could be different in IMRT. Intensity modulated radiation therapy modulates the beams to 
produce the dose distribution that matches the complex target shape (Figure 1-3). To modulate 
the beams, they are divided into beamlets and a mathematical model is formed that relates the 
intensity of the beamlets to the quality of the dose distribution to structures[33], [34]. Finally, the 
mathematical model is optimized to obtain the beamlets’ intensity that produces the desired dose 
distribution. 
Let x be the beamlet weight, fi(x) be the function defined for the i
th structure, and then intensity 
modulated radiation therapy solves the following function to find the optimal beamlet intensity: 
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒 ∑ 𝑤𝑖𝑓𝑖(𝑥)
𝑖∈𝑆
 . 
The wi is the weight parameter that reflects the importance of the i
th structure in the overall 
optimization.  
1.1.2 Challenges in Intensity Modulated Radiation Therapy 
Intensity Modulated Radiation Therapy (IMRT) has multiple conflicting goals, and the IMRT 
optimization seeks to find the dose distribution that produces the best trade-off in the conflicting 
goals. Traditional IMRT optimization assigns a weight to each goal and the planner can change 
the weight parameters to reflect the importance of the goal in the optimization. But the planner 
doesn’t know the exact weight parameters that produce the best trade-off in the dose distribution. 
Figure 1-4 shows the typical process used by the planner to find the value of the weight 
parameters. The planner guesses the weight parameters and runs the optimization to optimize 
dose distribution. The optimized dose distribution is examined to determine the quality of dose 
distribution. Typically, the dose distribution of the first round of the optimization does not satisfy 
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the clinical criteria. The planner tweaks the weight parameters and reruns the optimization until 
the desired dose distribution is found. Thus, treatment planning became a trial and error process 
rather than an ideal automated process because of the trial and error iterations in determining the 
weight parameters of the optimization. 
 
Figure 1-4 The treatment planning optimization workflow to determine the value of the weight 
parameters. The planner guesses the weight parameters and runs the optimization to optimize dose 
distribution. Typically, treatment planning optimization requires multiple iterations to produce the desired 
dose distribution. The planner tweaks the weight parameters and reruns the optimization until the desired 
dose distribution is found. 
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1.2 Multi-Objective Optimization Problem 
Intensity Modulated Radiation Therapy is a multi-objective optimization problem. IMRT 
optimization has an objective function for each structure included in the planning and optimizes 
the objectives to produce the desired dose distribution. The multi-objective optimization does not 
have a unique optimal solution[35]–[39]. Therefore, the optimal solution of the multi-objective 
optimization problem is defined in terms of the Pareto optimality[40].    
Mathematically, the multi-objective optimization problem can be defined as: 
Let x =[ x1 ,x2…, xn] be the n-dimensional decision vector and f1(x),f2(x)…fm(x) be the m 
objective functions, then the multi-objective optimization problem can be formulated as: 
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒[𝑓1(𝑥), 𝑓2(𝑥), … , 𝑓𝑚(𝑥)], 
𝑆𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜: 
𝑥 ∈ 𝑆 , 
Where S is the set of constraints and defines the feasibility region of the optimization problem.  
The optimal solution of the multi-objective optimization problem is defined in terms of the 
Pareto optimality. 
Let x1 and x2 be two solutions of the multi-objective optimization problem, then the solution x2 is 
said to be Pareto dominant over the x1 if: 
1. f(x2)≤f(x1) for all functions in the optimization 
2. f(x2)<f(x1) for at least one function in the optimization 
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A solution x* is said to be Pareto optimal if it is Pareto dominant over all solutions of the multi-
objective optimization problem. We cannot improve on an objective without making another 
objective worse off when we have a Pareto optimal solution.   
The set of all Pareto optimal solutions forms a Pareto frontier. Figure 1-5 shows the Pareto 
frontier for two objective functions. We assumed that the optimization problem minimizes the 
function f1(x) and f2(x). The set of points {a,b,c,d,e} defines the Pareto frontier of the 
optimization problem.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5 The optimal solution of the multi-objective optimization problem. The x-axis shows the first 
objective and the y-axis shows the second objective. The Pareto frontier displays all of the Pareto optimal 
solutions of the f1(x) and f2(x)[41]. 
Pareto Frontier 
Worse 
Better 
Better 
Worse 
f2(x) 
f1(x) 
Pareto frontier 
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1.3 Goal Programming 
There has not been a direct method to solve the multi-objective optimization problem. Therefore, 
the multi-objective optimization problem must be transformed into a form that can be solved 
using the existing optimization algorithms. Goal programming transforms the multi-objective 
optimization problem into a form that can be solved using the existing optimization algorithms 
[42]–[55]. The goal programming approach assigns the numeric value for each objective in the 
optimization. The optimization finds the solution that minimizes the deviation from the stated 
goal. Let f(x) is an objective function, "d" is a numerical value for the objective function, and 
then there are three types of goals: 
1) f(x)>=d sets the lower limit in the objective function f(x) and is called lower limit, one-
sided goal. 
2) f(x)<=d sets the upper limit for the objective function and is called upper limit one-sided 
goal function. 
3) d1<=f(x)<=d2 sets the upper and lower limit in the objective function and is called two-
sided goal. 
The IMRT optimization was solved using the goal programming approach. The objective 
functions of IMRT optimization are turned into goals by assigning a numerical value to the 
objective function. The goal for the target structure is to produce the prescribed dose to each 
voxel of the structure, while the goal for the normal structure is to push the dose as low as 
possible. Therefore, the target voxel that receives more than the prescribed dose is penalized in 
the optimization. Similarly, the dose of normal structure is minimized to push the dose as low as 
possible.   
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There are two ways to solve goal programming problems based on how the priorities of the goals 
are handled: 
 Non-preemptive goal programming 
 Pre-emptive goal programming 
1.3.1 Non-Preemptive Goal Programming 
Non-preemptive goal programming assigns almost the same priority to all of the goals in the 
optimization[56], [57]. The goals are weighted and combined to form a single objective function, 
which is minimized to find an optimal solution. The problem designer should have a good 
understanding of the problem domain to assign the weight to each goal of the optimization. For 
instance in IMRT optimization, the target goals are assigned higher weight than the normal 
structure. Mathematically, non-preemptive goal programming is formulated as follows: 
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒 ∑ 𝑤𝑖(𝑓𝑖(𝑥) − 𝑑𝑖)
2
𝑛
𝑖=1
 ,   
di is the desired value of the function fi(x) and wi is the weight assigned to the i
th goals. 
1.3.2 Preemptive Goal Programming 
Preemptive goal programming prioritizes the goals of the optimization and solves the goal based 
on its priority level [57]. If there is more than one goal of the same priority, they can be 
combined as in the non-preemptive method. The idea behind the preemptive goal programming 
is that the higher priority goal can’t be sacrificed to improve on the lower priority goals. The 
result of the higher priority goals is converted into the constraint while solving the lower priority 
goals. For instance in IMRT optimization, the target goal has the highest priority, the rectum has 
the second priority and the bladder and the femur have the third priority. Preemptive goal 
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programming optimizes the target structure goal. The result of the target structure goal is 
converted into the constraint while optimizing for the rectum structure goal. Finally, the result of 
the target and the rectum structure goal is converted into the constraint while optimizing for the 
bladder and the femur goals. 
In this dissertation, we used hierarchical optimization to solve the multi-objective IMRT 
optimization problem. Hierarchical optimization is the preemptive goal programming approach. 
The preemptive approach is an attractive choice to solve the IMRT optimization as it has the 
potential to automate the treatment planning process. However, the problem size of the 
preemptive approach is larger than that of the non-preemptive approach, and thus increases the 
computational time. We will discuss the sampling approach in reducing the optimization time in 
the next chapter. 
1.4 Outline  
The dissertation is organized into five chapters. Chapter 2 discusses boundary and interior voxel 
sampling to reduce the hierarchical optimization time. We demonstrated that the optimization 
time could be reduced by including all of the boundary voxels and sampling the interior voxels 
of a structure in a quasi-random fashion. Chapter 3 discusses customizing the high-performance 
nonlinear optimization interior point solver (IPOPT) to solve the hierarchical optimization 
problem. In Chapter 4, we formulated the mathematical model needed to automate the treatment 
planning process. We automatically prepared the treatment plans of 31 prostate patients using the 
mathematical formulation and compared the treatment plans prepared using the hierarchical and 
Eclipse treatment planning systems. Finally, Chapter 5 summarizes the dissertation work.  
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Chapter 2: Sampling 
As we discussed in the previous chapter, hierarchical optimization increases the problem size by 
introducing new constraints in the problem formulation. The increase in the problem size 
increases the computational time of the optimization. In this chapter, we proposed a sampling 
algorithm to reduce the computational time of hierarchical optimization. 
2.1 Introduction 
Intensity-modulated radiation therapy (IMRT) offers many additional degrees of freedom 
compared to conformal radiotherapy techniques (namely, the "beamlet" intensity and variables), 
thereby enabling a high degree of control over the shape and intensity of the high dose region 
within a patient [58]–[62]. This is reflected in the typical computational formulation of the 
planning problem in a large number of "beamlet" intensity variables that together comprise 
deliverable beams of radiation. Unfortunately, the added degrees of freedom greatly increase the 
complexity of treatment planning[63]–[66].  Conventional treatment planning algorithms attempt 
to cope with this complexity through an array of structure-specific weights and dosimetric goals 
that the user modifies during planning [67]. Currently, the IMRT treatment planning has not yet 
approached the ideal of automated, ‘inverse planning,’ and is typically a time-consuming, "trial-
and-error" process with user-modified input parameters. Some approaches to improve this 
process have been proposed[68]–[75]. In particular, newer methods [69] based on goal 
programming methodologies that avoid the need for tuning parameters to a given patient. 
Another approach is to parallelize a simplified (quadratic) formulation of the planning problem, 
which might be particularly well-suited to fast, online adaptations of treatment plans [76]. But 
these improved methods still require the solution of large-scale optimization algorithms. 
Therefore, time efficiency remains an unachieved, but essential computational goal if it can be 
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obtained at a negligible cost to accuracy.     
During inverse planning for IMRT, radiation beams at a given gantry angle are further converted 
into discrete "beamlets," resulting in a beam intensity profile that can be decomposed into sub-
fields delivered using a multi-leaf collimator. In state of the art algorithms, the dose that each 
beamlet contributes to each voxel is computed once for fluence of arbitrary intensity and stored 
in a large "influence matrix," which typically has millions of rows (number of voxels in the dose 
calculation volume) and thousands of columns (the number of beamlets), resulting in billions of 
elements. During optimization, the computer must multiply the influence matrix by the beamlet 
weight vector hundreds of times. Memory requirements are a challenge as well because 
accessing large memory blocks outside of on-chip cache is a slow process [77]–[80].  
Additionally, since the solution time usually increases as a polynomial of the problem size, large 
influence matrices typically correspond to much longer solution times. Therefore, methods to 
reduce the size of the problem statement are needed. 
The general idea of voxel sampling has been explored previously by Martin, et al. [81], who used 
sampled voxels to compute estimates of the gradient and objective functions to solve the 
optimization problem. Because doses for nearby voxels are related, some groups have utilized 
voxel clustering. For example, Scherrer, et al. [82] introduced an adaptive voxel clustering 
method to increase the speed of optimization; however, the method is complex and ensuring final 
solution quality can be difficult. The Computational Environment for Radiotherapy Research 
(CERR), in the ORART Toolbox graphical user interface (GUI) [83], provides for gridded 
down-sampling of low-dose beamlet scatter values. Rocha, et al. [84] studied the impact of 
different sampling rates in treatment planning using sampling methods available in CERR. 
Increasing the sampling rate in CERR results in larger voxel size and thus deteriorates the dose 
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distribution in organs. Lu, et al. [85] studied the performance of random and grid sampling 
methods. Using various metrics they determined that grid sampling is relatively efficient and 
accurate. Another commonly used approach eliminates low-dose contributions from a given 
beamlet in the influence matrix [71], [86]. Voxel sampling has also been used in beam angle 
optimization. Ferris, et al. [87] developed an adaptive algorithm that uses three phases for beam 
angle optimization. The first phase uses coarse sampling to determine the most promising beam 
angles and is refined in subsequent phases.  
Most of the sampling methods discussed in the literature are for unconstrained, optimization 
problem formulation. Some methods require multiple passes to refine the sampling process. 
These methods may not be suitable for the large-scale, constrained, optimization problem that 
often arises while automating the treatment plan.  
In this paper, we propose a voxel sampling method; referred to as "Boundary and Interior 
Sampling," or "BIS," to reduce the computational time of the constrained IMRT optimization 
problem. We used a prioritized prescription algorithm[88] to demonstrate the BIS method. The 
prioritized prescription formulation is attractive because it offers greater control over the 
problem statement and the potential for more automation than the weighted sum objective 
function approach. The purpose of prioritization is also to ensure that higher priority dose-
volume planning goals are not sacrificed to improve lower priority goals. The algorithm has four 
steps. The first optimizes dose to the target structures while sparing key sensitive organs from 
radiation. In the second, the algorithm finds the best beamlet weight to reduce toxicity risks to 
normal tissue while holding the objective function achieved in the first step as a constraint, with 
a small amount of allowed slip. Likewise, the third and fourth steps introduce lower priority 
normal tissue goals and beam smoothing, as further discussed below. 
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2.2 Methods 
We tested the Boundary and Interior sampling (BIS) algorithm on seven different 
anonymized/non-identifiable head and neck treatment planning datasets. The treatment plans, 
after importing into CERR, had slices of 256 x 256 with voxels of size 0.2 × 0.2 cm; the slice 
thickness was 0.5 cm. We used seven equispaced beams of energy 6MV to create the treatment 
plan.  
2.2.1 Optimization Formulation 
The optimization formulation was based on hierarchical optimization[88]. Hierarchical 
optimization prioritizes objectives from most to least important and solves them one at a time. 
The optimization has four steps as discussed below. 
Step I 
The goal of the first step is to achieve good target coverage while satisfying the hard constraints 
in the normal structures. Let T be the set of target structures, RI be the set of normal structures, 
𝐷𝑖
𝑝𝑟𝑒
 be the prescription dose to the target structure i, and 𝐷𝑗(𝑤) be the actual dose to the voxel j 
of the target structure. 
The dose to target structures was optimized in the first step in the presence of the hard 
constraints of the normal structures. Let S be the set of structures in the first step. Then,     
𝑆 = {𝑖| 𝑖 ∈ 𝑇 ∪ 𝑅𝐼} (2-1) 
The dose 𝐷𝑗(𝑤) to the voxel j of a structure is given by 
𝐷𝑗(𝑤) = ∑ 𝐴𝑖𝑗 ∗ 𝑤𝑗             ∀𝑖 ∈ 𝑆
𝑛
𝑖=1   (2-2)  
Matrix A contains the dose to each voxel of structures due to the unit beamlet fluence and is 
called the influence matrix. The influence matrix is of the size m by n, where m indicates the 
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total number of voxels in the structures and n indicates the total number of beamlets in the 
treatment. 
Let Vi be the set of voxels before sampling, and  𝑉𝑖
′ be the set of voxels after sampling for the 
structure i. The optimization formulation is as follows:     
Minimize
  𝐹𝐼(𝑤) =  ∑ (
1
|𝑉𝑖
′|
 ∑ [𝐷𝑗(𝑤) − 𝐷𝑖
𝑝𝑟𝑒
𝑗∈𝑉𝑖
′
]2) + ∑ 𝑡𝑖
2,
𝑖∈𝑇𝑖∈𝑇
 
(2-3)   
Subject to   
 
  
𝐷𝑖
𝑝𝑟𝑒 − 𝐷𝑗(𝑤) ≤ 𝑡𝑖                     ∀𝑖 ∈ 𝑇, (2-4) 
 
  
0.05 ∗ D𝑖
𝑝𝑟𝑒 ≤ 𝑡𝑖                         ∀𝑖 ∈ 𝑇, (2-5) 
  𝐷𝑖
𝑚𝑖𝑛 ≤ 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥             ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖
′, (2-6) 
 
  
𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                         ∀𝑖 ∈ 𝑅𝐼 , 𝑗 ∈ 𝑉𝑖
′, (2-7) 
  𝑤𝑖 ≤ 𝑤
𝑚𝑎𝑥 .                                                          (2-8) 
 
The under-dose region is undesirable in the target structure. The under-dose region of the target 
structure was penalized by putting the upper bound (ti) on the deviation of the target dose in (2-4) 
and minimizing the upper bound, ti, in the objective function. Finally, the maximum dose to the 
target and normal structures was constrained in (2-6) and (2-7).    
Step II 
The goal of the second step is to minimize dose to the brainstem while preserving the solution of 
the first step. We used the mean dose to α% of the brainstem voxels to reduce dose in the high 
dose region of the brainstem. Similarly, we used the constraints to preserve the dose to the 95% 
region of the target structure. Although the “no-sampling” (NS) approach uses only the 
constraints to preserve the target dose, the BIS approach uses the additional penalty term in the 
objective function to maintain the homogeneity of the target dose. In NS, the constraints were 
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applied to each voxel of the target structures to maintain homogenous dose distribution to target 
structures, whereas, in the BIS method, the constraints were applied only to the sampled voxels 
of target structures. The BIS method had no constraints to maintain homogeneous dose to non-
sampled regions of target structures; thus BIS produced non-homogenous dose distribution to 
target structures. To prevent dose deviations in the non-sampled region of target structures, the 
targets voxels dose deviates from the maximum to the minimum and is penalized in the objective 
function.  
Let RII denote the set of structures in the second step, FI denote the objective function of the first 
step, and wI denote the optimal beamlet weight of the first step. The optimization formulation is 
given by: 
  
Minimize 
𝐹𝐼𝐼(𝑤) =  ∑ (𝑦𝑖
𝛼 +
1
(1 − 𝛼)|𝑉𝑖
′|
∑ 𝑝𝑗𝑖
𝛼
|𝑉𝑖
′|
𝑗=1
)
𝑖∈𝑅𝐼𝐼
 
+ ∑ ∑ (𝛾
𝑗∈(𝑉𝑖−𝑉𝑖
′)𝑖∈𝑇
∗ (min (0, 𝐷𝑖
𝑚𝑎𝑥 − 𝐷𝑗)
2 + 𝜑 ∗ max (0, 𝐷𝑖
𝑚𝑖𝑛 − 𝐷𝑗)
2
) , 
 (2-9)    
Subject to   
 𝐷𝑗 − 𝑧𝑖𝑗 = 0                                    ∀i ∈ 𝑅
𝐼𝐼 , j ∈ 𝑉𝑖
′, (2-10)   
 𝑝𝑗𝑖
𝛼 ≥ 0,                                                                         (2-11)   
 𝑝𝑗𝑖 + 𝑦𝑖
𝛼 − 𝑧𝑗𝑖 > 0                         ∀𝑖 ∈ 𝑅
𝐼𝐼 , j ∈ 𝑉𝑖
′, (2-12)   
 𝐹𝐼(𝑤) ≤ (1 + 𝑠) ∗ 𝐹𝐼(𝑤𝐼)                                                                                                    (2-13)
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 𝐷𝑖
𝑚𝑖𝑛 ≤ 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                   ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖
′,       
(2-14)   
 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                                  ∀𝑖 ∈ 𝑅𝐼 , 𝑗 ∈ 𝑉𝑖
′,  (2-15)   
 𝑤𝑖 ≤ 𝑤
𝑚𝑎𝑥.                                                                     (2-16)   
 
The formulation of step II is based on the mean-tail-dose formulation[89], [90]. The mean-tail-
dose formulation introduces the artificial variable p, y and z to minimize the mean dose to the 
hottest α% region ( (2-9) - (2-12)). The parameters γ and φ in  (2-9) control the deviation of the 
target dose from the maximum and minimum dose. 
The slip parameter "s" was used in (2-13) to relax the target dose distribution. The target dose 
was relaxed by almost 60% in the second step. The maximum dose to target and normal 
structures was constrained by the equations (2-14) and (2-15). 
Step III 
The third step minimizes the average dose to normal structures while preserving the solution of 
the first and second step. Following is the optimization formulation for the third step: 
Minimize 
𝐹𝐼𝐼𝐼(𝑤) =  ∑
1
|𝑉𝑖
′|
∑ 𝐷𝑗(𝑤)
𝑗∈𝑉𝑖
′𝑖∈𝑅𝐼𝐼𝐼
+ ∑ ∑ (𝛾
𝑗∈(𝑉𝑖−𝑉𝑖
′)𝑖𝜖𝑇
∗ (min (0, 𝐷𝑖
𝑚𝑎𝑥 − 𝐷𝑗)
2 + 𝜑 ∗ max (0, 𝐷𝑖
𝑚𝑖𝑛 − 𝐷𝑗)
2
) , 
    (2-17) 
 
Subject to   
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 𝐷𝑗 − 𝑧𝑖𝑗 = 0                            ∀i ∈ 𝑅
𝐼𝐼 , j ∈ 𝑉𝑖
′,     (2-18)     
 𝑝𝑗𝑖
𝛼 ≥ 0,                                                                     (2-19)   
 𝑝𝑗𝑖 + 𝑦𝑖
𝛼 − 𝑧𝑗𝑖 > 0                  ∀𝑖 ∈ 𝑅
𝐼𝐼 , j ∈ 𝑉𝑖
′,     (2-20)   
 
∑ (𝑦𝑖
𝛼 +
1
(1 − 𝛼)|𝑉𝑖
′|
∑ 𝑝𝑗𝑖
𝛼
|𝑉𝑖
′|
𝑗=1
)
𝑖∈𝑅𝐼𝐼
≤ 𝑀𝛼
∗𝑖      ∀𝑖 ∈ 𝑅𝐼𝐼 , 
    (2-21)   
 𝐹𝐼(𝑤) ≤ (1 + 𝑠)2 ∗ 𝐹𝐼(𝑤𝐼),     (2-22) 
 𝐷𝑖
𝑚𝑖𝑛 ≤ 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥              ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖
′,    (2-23) 
 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                           ∀𝑖 ∈ 𝑅𝐼 , 𝑗 ∈ 𝑉𝑖
′,    (2-24) 
 𝑤𝑖 ≤ 𝑤
𝑚𝑎𝑥.                                                                 (2-25) 
 
The constraints     (2-18) to     (2-21) preserve the mean dose to the hottest α% region of the 
normal structure obtained in the second step (𝑀𝛼
∗𝑖). Mathematically 𝑀𝛼
∗𝑖 is given by,  
𝑀𝛼
∗𝑖  = ∑ (𝑦𝑖
∗𝛼 +
1
(1 − 𝛼)|𝑉𝑖
′|
∑ 𝑝𝑗𝑖
∗𝛼
|𝑉𝑖
′|
𝑗=1
)     ∀𝑖 ∈ 𝑅𝐼𝐼
𝑖∈𝑅𝐼𝐼
 
               (2-26) 
 
Similarly, the constraints     (2-21) and     (2-22) preserved the dose to the target structure 
obtained in the first step. The slip parameter was doubled to relax the target dose constraints so 
that the dose to the normal structure could be improved.  
Step IV 
The fourth step smooths the beam profiles, removes the hot spots outside the target structure and 
produces the deliverable plan. The optimization formulation is as follows: 
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Minimize 
𝐹𝐼𝑉(𝑤) =  ∑ 𝑤𝑖
2
𝑛
𝑖=1
, 
     (2-27) 
Subject to   
 
∑ (𝑦𝑖
𝛼 +
1
(1 − 𝛼)|𝑉𝑖
′|
∑ 𝑝𝑗𝑖
𝛼
|𝑉𝑖
′|
𝑗=1
)
𝑖∈𝑅𝐼𝐼
≤ 𝑀𝛼
∗𝑖      ∀𝑖 ∈ 𝑅𝐼𝐼 , 
(2-28) 
 𝐷𝑗 − 𝑧𝑖𝑗 = 0                            ∀i ∈ 𝑅
𝐼𝐼 , j ∈ 𝑉𝑖,      (2-29) 
 𝑝𝑗𝑖
𝛼 ≥ 0                                                                 (2-30) 
 𝑝𝑗𝑖 + 𝑦𝑖
𝛼 − 𝑧𝑗𝑖 > 0                  ∀𝑖 ∈ 𝑅
𝐼𝐼 , j ∈ 𝑉𝑖
′, (2-31) 
 
                𝐹𝐼(𝑤) ≤ (1 + 𝑠)3 ∗ 𝐹𝐼(𝑤𝐼),                                            (2-32) 
 𝐷𝑖
𝑚𝑖𝑛 ≤ 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥             ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖
′,  (2-33) 
 
 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                            ∀𝑖 ∈ 𝑅𝐼 , 𝑗 ∈ 𝑉𝑖
′,  (2-34) 
 
∑
1
|𝑉𝑖|
∑ 𝐷𝑗(𝑤)
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼𝐼
≤ 𝑀𝐼𝐼𝐼
∗ ,              
 (2-35) 
 𝑤𝑖 ≤ 𝑤
𝑚𝑎𝑥.                                                                   (2-36) 
 
Note that the constraints (2-28) -  (2-34) in the fourth step are same as in the third to preserve the 
solution of the first and second steps. The only difference is in the slip parameter, which was 
increased to (1+s)3 to relax the target dose constraint. The fourth step has added a constraint  
(2-35) to preserve the average dose to the normal structures (𝑀𝐼𝐼𝐼
∗ ) obtained in the third. 
Mathematically, the average dose to the normal structure (𝑀𝐼𝐼𝐼
∗ ) is given by, 
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𝑀𝐼𝐼𝐼
∗  = ∑
1
|𝑉𝑖|
∑ 𝐷𝑗(𝑤 ∗)
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼𝐼
 
   (2-37) 
2.3 Smaller Slip value for Sampling 
We found that the slip value, a parameter used in hierarchical optimization, should be kept 
smaller in the BIS formulation than in the NS formulation. Hierarchical optimization uses 
constraints to preserve the solution of the higher priority goals while solving for the lower 
priority goals. The result of the higher priority goal is multiplied by a slip factor 1+s (s>0) to 
relax constraints so that the solution of the lower priority goals may be improved. Since BIS 
degrades the solution of higher priority goals compared to NS, the value of "s" was decreased 
from 1 to 0.6 to preserve the solution of higher priority goals. 
2.4 Sampling scheme 
 
Because photon beams must pass through boundaries and boundaries are of a lower dimension 
than volumes, they are attractive for inclusion in non-uniform sampling schemes. We, therefore, 
include all boundary voxels in our sampling methods. A voxel is considered a boundary voxel if 
there are no voxels surrounding it in at least one of the four directions in 2D (left, right, up, 
down) from the same region. Otherwise, the voxel is considered an interior voxel.  
A k-means clustering algorithm was used to sample inner-voxels of targets and critical normal 
structures (i.e., structures like the brainstem, which have a hard maximum dose constraint) in 
quasi-random fashion. The k-means clustering algorithm forms clusters of voxels that are similar 
to each other and, therefore, requires a similarity measure; the influence matrix was used to 
estimate voxel similarity.  
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If p is the percentage of inner-voxels that will be selected in quasi-random fashion, then the 
number of voxels to be sampled from each cluster is the rounded integer of the number of voxel 
points divided by p. Thus, the actual sampling rate is discontinuous as a function of p. This 
discontinuity is ameliorated for larger sampling rates of p by using a larger cluster size, but is 
unavoidable for smaller values of p, if we remain consistent with a quasi-random coverage of the 
structure. Given the goal of achieving quasi-uniform sampling, the number of clusters is reduced 
when the sampling rate is high. This leads to relatively uniform coverage, irrespective of whether 
there are fewer or a larger number of clusters with a lower sampling rate.  
In practice, the number of clusters is calculated by dividing the total number of voxels in a region 
of interest by the minimum number of voxels in each cluster. The minimum number of voxels in 
each cluster equals the percentage of inner-voxels (p) that are to be sampled. Therefore, the 
number of clusters for a structure is given by: 
Number of clusters = 
|Vi |
p
 
(2-38) 
2.5 Experimental Results 
We ran the BIS and NS algorithms in seven head and neck treatments plans to compare the dose 
quality, computational time and memory required for the optimization process. We found that 
BIS could reduce the computational time and memory while maintaining the dose quality.  
2.5.1 Determining the best Sampling Rate 
We plotted the average root mean square error and the optimization run time to determine the 
best inner voxel sampling rate (Figure 2-1). Including a small fraction of interior voxels (around 
5%) decreased the root mean square error from 2.5% to less than 1%. As seen in Figure 2-1, 
although the sampling rate was increased, the average root mean square error was almost the 
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same when the sampling rate was greater than 5%. Therefore, we chose the sampling rate based 
on the optimization run time.  
We observed that the sampling rate of 10% took the least amount of time to solve the 
optimization problem. The optimization time was the highest when no inner voxels were 
included in the optimization because our method controls the dose to the non-sampled regions of 
target structures to produce a homogenous dose distribution after the first step. When target dose 
was optimized with the boundary voxels and no inner voxels (i.e., a sampling rate of 0%), a large 
fraction of the compute time in later steps was spent adjusting the dose to the non-sampled 
regions of target structures. However, the time to fix the target dose was small when a fraction of 
the inner voxels was included in the first step (Figure 2-1).  
 
Figure 2-1 IMRT optimization time with the different sampling rates, (a) the average root mean square 
error of the targets and brainstem for the sampling rate 0 to 100, (b) The boundary voxels were always 
included, and inner voxels were sampled at the different sampling rates. The 10% sampling rate gave the 
best trade-off in the optimization time and the solution quality. Therefore, we chose a sampling rate of 
10% for the optimization.  
(a) (b) 
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2.5.2 Run Time of BIS and No-Sampling Methods 
We used the time reported from the optimization solver to compare the run time of BIS and the 
no-sampling method. We found that BIS produced different speed-ups depending on the 
treatment data. The minimum speedup was a factor of 1.80 for treatment plan 3; the maximum 
was 2.64 for treatment plan 5. Thus, BIS produced an average speed-up of 2.04 compared with 
standard sampling (Table 2-1 ).  
Table 2-1 The speed-up in the optimization time using the boundary and interior sampling (BIS) method 
(for sampling rate 10%) compared with the no-sampling method is tabulated; the sampling method was 
faster than the no-sampling method. 
 Time (Minutes)  
Plan Sampling No-sampling Speedup 
1 5.11 11.56 2.26 
2 16.83 25.41 1.50 
3 4.62 8.33 1.80 
4 8.74 17.21 1.96 
5 3.8 10.04 2.64        
6 6.53 15.05 2.30 
7 13.67 25.01 1.82 
 
2.5.3 Dose Distribution of BIS and No-Sampling Methods 
We plotted dose-volume histograms and dose-color-wash displays (Figure 2-3 to Figure 2-8) for 
head and neck sites to compare the dose obtained from BIS and no-sampling (NS) methods. The 
first step in the process optimized the dose to target structures. To compare the doses to target 
structures, we computed D95 of each of the target structures using the treatment plan obtained 
from BIS and NS. 
The D95 obtained from BIS was almost the same as that obtained from NS. Out of seven head 
and neck treatment plans, one treatment plan had lower, one had equal, and five treatment plans 
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had higher D95 from BIS than from NS. The D95 obtained from BIS was 0.29% lower than that 
obtained from the NS for one treatment plan. Similarly, on average, the D95 obtained from BIS 
was 0.36% higher than that obtained from the NS for the five treatment plans. The results show 
that the target coverage from the sampling is comparable with that of NS. 
The second step of hierarchical optimization minimized the mean dose of the hottest 1% 
(MOHx) of the brainstem voxels. The dose to the brainstem obtained from BIS was comparable 
to that obtained from the NS. On average, the MoHx obtained from BIS was 0.6% higher than 
that obtained from the NS for the two treatment plans. The results show that the dose to the 
brainstem obtained from BIS was equivalent to that of NS. 
The third step of hierarchical optimization minimized the mean dose to normal structures. There 
were a number of normal structures in the optimization and we chose the spinal cord as a 
representative structure to show the dose to the normal structure. The dose to the spinal cord 
obtained from BIS was comparable to that obtained from NS. On average, the mean dose to 
spinal cord obtained from BIS was 5.19% less than that obtained from NS. The result indicates 
that BIS minimized radiation exposure to the normal structures. 
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Figure 2-2 a) Dose color wash and b) dose-volume histogram produced in the boundary and interior 
sampling (BIS) and no-sampling methods for head and neck treatment plan 1. The BIS and no-sampling 
methods produced almost the same dose distribution. Therefore, the dose-volume histogram of BIS and 
no-sampling almost overlap and the dose color wash produced in BIS and no-sampling have similar 
colors. 
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Figure 2-3 a) Dose color wash and b) dose-volume histogram produced in the boundary and interior 
sampling (BIS) and no-sampling methods for head and neck treatment plan 2. The BIS and no-sampling 
methods produced almost the same dose distribution. Therefore, the dose-volume histogram of BIS and 
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no-sampling almost overlap and the dose color wash produced in BIS and no-sampling have similar 
colors. 
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Figure 2-4 a) Dose color wash and b) dose-volume histogram produced in the boundary and interior 
sampling (BIS) and no-sampling methods for head and neck treatment plan 3. The BIS and no-sampling 
methods produced almost the same dose distribution. Therefore, the dose-volume histogram of BIS and 
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no-sampling almost overlap and the dose color wash produced in BIS and no-sampling have similar 
colors. 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
Figure 2-5 a) Dose color wash and b) dose-volume histogram produced in the boundary and interior 
sampling (BIS) and no-sampling methods for head and neck treatment plan 4. The BIS and no-sampling 
methods produced almost the same dose distribution. Therefore, the dose-volume histogram of BIS and 
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no-sampling almost overlap and the dose color wash produced in BIS and no-sampling have similar 
colors.   
 
 
 
 
 
 
 
 
 
 
 
     b) 
 
 
 
 
 
 
 
 
Figure 2-6 a) Dose color wash and b) dose-volume histogram produced in the boundary and interior 
sampling (BIS) and no-sampling methods for head and neck treatment plan 5. The BIS and no-sampling 
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methods produced almost the same dose distribution. Therefore, the dose-volume histogram of BIS and 
no-sampling almost overlap and the dose color wash produced in BIS and no-sampling have similar 
colors.  
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Figure 2-7 a) Dose color wash and b) dose-volume histogram produced in the boundary and interior 
sampling (BIS) and no-sampling methods for head and neck treatment plan 6. The BIS and no-sampling 
methods produced almost the same dose distribution. Therefore, the dose-volume histogram of BIS and 
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no-sampling almost overlap and the dose color wash produced in BIS and no-sampling have similar 
colors.  
 
 
 
 
 
 
 
 
 
 
                              
Figure 2-8 a) Dose color wash and b) dose-volume histogram produced in the boundary and 
interior sampling (BIS) and no-sampling methods for head and neck treatment plan 7. The BIS 
and no-sampling methods produced almost the same dose distribution. Therefore, the dose-
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volume histogram of BIS and no-sampling almost overlap and the dose color wash produced in 
BIS and no-sampling have similar colors.  
2.6 Memory Used by BIS and No-Sampling Methods 
We collected the computational memory used by BIS and NS to compare the memory usage of these 
methods. The BIS method reduced the problem size, which ultimately decreased the memory used in the 
optimization by 40% ( 
Figure 2-9). 
 
 
 
 
 
 
 
 
 
Figure 2-9 Memory used by the boundary and interior sampling (BIS) and no-sampling methods in IMRT 
optimization. The BIS method has less voxels compared to the NS methods. Therefore, BIS used less 
memory than the NS method. 
2.7 Discussion 
This study demonstrates that Boundary and Interior Sampling (BIS) could significantly reduce 
the time and memory used by large-scale, constrained, IMRT optimization without substantially 
degrading dose distributions to organs. The average speedup of the sampling was 2.04 compared 
to that of no sampling (NS). The difference in D95 to the target structure by the sampling was 
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less than 1%, and sampling produced a lower dose to normal organs than that produced by NS. 
We hypothesized that the most important voxels for controlling interior dose distributions were 
actually the boundary voxels. Optimal results were obtained by including approximately 10% of 
inner voxels sampled using quasi-random cluster sampling to reduce the occurrence of large 
"holes" in the regions of interest. 
The sampling method proposed by Martin, et al.[81] used the steepest descent algorithm[91] to 
solve the optimization problem. However, the steepest descent algorithm cannot solve the 
constrained optimization problem. One way to use the steepest descent algorithm to solve the 
constrained optimization is to project the gradient into the feasible space to satisfy the constraints 
in the problem. The projected gradient may not give a good decrease in the objective function 
and the algorithm might require large iterations to converge to an optimal solution. In contrast, 
BIS solved the large-scale constrained optimization problem using the open source IPOPT [1] 
optimization solver. 
Scherrer, et al. [82]  proposed a voxel clustering method that requires knowledge about the 
solution space to cluster the voxels. They solved an approximation of the original problem to 
probe the solution space, which is a challenging task. Boundary and Interior sampling does not 
require complex initialization steps and can directly solve the original problem.  
The sampling method proposed by Ferris, et al. [87] solves the problem in three phases. They 
used coarse sampling in the first phase and refined the sampling in subsequent phases. The 
Ferris, et al. method requires multiple passes to solve the optimization problem, but our sampling 
method does not; thus making it an attractive choice to solve a multi-step optimization problem. 
In summary, the Boundary and Interior Sampling (BIS) method was 1.8 to 2.64 times faster than 
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the standard approach with NS. As a consequence, BIS used around 40-50% of the memory 
needed without sampling. Dose distribution metrics (such as D95) computed using BIS were 
comparable (typically within 1%) with that of the NS method. It is recommended to use a full 
dose calculation after optimization to create reportable metrics.  
2.8 Conclusions 
The computational complexity of the IMRT treatment planning problem, especially promising 
but complex approaches such as prioritized prescription optimization, motivated our proposed 
sampling method. We have demonstrated, for a range of treatment plans that a combination of 
boundary and partial, quasi-random, interior sampling results in a high-quality IMRT solution.  
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Chapter 3: Integrating High-Performance 
Nonlinear Solver 
3.1 Introduction 
The previous chapter studied the sampling method to reduce the computational time of 
hierarchical optimization. Hierarchical optimization is a large-scale nonlinear optimization 
problem. The efficient nonlinear solver is needed to solve such a large-scale optimization 
problem. This chapter focuses on adopting the general purpose open source nonlinear solver to 
solve the hierarchical optimization problem.  
There are several commercial and open-source treatment planning applications to perform IMRT 
optimization [92]–[94]. Most of these applications use the weighted sum of objective functions 
for optimization. The weighted sum approach of solving the treatment planning optimization 
makes the treatment planning process a manual trial and error process. Therefore, there has been 
considerable research in automating the treatment planning process using hierarchical 
optimization [69], [72], [73]. However, automating the treatment planning application requires 
the ability to solve the large-scale constrained optimization problem, which is why we adopted 
the open source Interior Point Optimization (IPOPT) solver. We studied the memory access 
pattern of the large-scale matrices and reduced the computational time required to solve the 
optimization problem. Our application is integrated with the Computational Environment for 
Radiotherapy Research (CERR), a widely used software platform to develop and share radiation 
therapy treatment planning research[95]; thus providing a complete flow of information for the 
IMRT treatment planning process. We found that improved memory access reduced memory 
latency, which ultimately decreased the IMRT optimization time.   
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3.2 Methods 
We developed a software application in C++ to solve the large-scale nonlinear hierarchical 
optimization and investigated the impact of the memory access pattern in run time of the 
optimization. We prepared treatment plans of seven head and neck plans using the software 
application.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Illustration of the treatment planning application. The application communicates with 
Computational Environment for Radiotherapy Research (CERR) to read input data for optimization and 
uses an Interior Point Optimizer (IPOPT) solver to perform the optimization. 
The application has four different modules: the CERR communicator, Optimization Formulation 
Implementation, Matrix Libraries and the Solver Communicator (Figure 3-1). The CERR 
communicator reads the influence matrix, which relates beamlet fluence to voxel dose as 
generated in the CERR using the ORART toolbox. The optimization formulation module 
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implements the hierarchical optimization formulation, which is a preemptive goal programming 
formulation[88]. The optimization problem was solved using  the IPOPT[96] solver.  
3.3 Optimization Formulation 
The optimization formulation is based on hierarchical optimization as discussed in section 2.1. 
The hierarchical optimization formulation prioritizes the treatment planning goals and solves one 
goal at a time. There are four steps in the optimization. The first step optimizes the dose to target 
structure. The second optimizes dose to critical structures while using constraints to preserve the 
dose to the target structures. The later steps of optimization introduce lower priority goals such 
as optimizing dose to normal structure and smoothing fluence profile.  
Step I 
The first step produces good target coverage while satisfying maximum dose constraints of 
normal structures. Let T be the set of target structures, RI be the set of normal structures, and 𝑉𝑖 
be the set of voxels in the structure i, then the set of all structures "S" in the first step of 
optimization is given by:  
𝑆 = {𝑖| 𝑖 ∈ 𝑇 ∪ 𝑅𝐼}    (3-1)  
 
To calculate dose to each structure, structures are discretized into voxels and beams are 
discretized into beamlets. If there are n number of beamlets in the treatment planning, then the 
dose to voxel j of a structure i is given by: 
𝐷𝑗(𝑤) = ∑ 𝐴𝑖𝑗 ∗ 𝑤𝑗                                  ∀𝑖 ∈ 𝑆
𝑛
𝑖=1                     (3-2 ) 
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The matrix "A" is m by the n influence matrix. The number of rows in the matrix equal to the 
number of voxels in the structures and the number of columns equal to the number of beamlets in 
the treatment. 
The first step minimizes the difference between the actual dose and the prescribed dose to 
produce good target coverage. The formulation is given below:   
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒 𝐹𝐼(𝑤) =  ∑ (
1
|𝑉𝑖|
 ∑ [𝐷𝑗(𝑤) − 𝐷𝑖
𝑝𝑟𝑒
𝑗∈𝑉𝑖 ]
2) + ∑ 𝑡𝑖
2
𝑖∈𝑇𝑖∈𝑇 ,     
    (3-3) 
𝑆𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜                     
                                        𝐷𝑖
𝑝𝑟𝑒 − 𝐷𝑗(𝑤) ≤ 𝑡𝑖                    ∀𝑖 ∈ 𝑇,     (3-4) 
0.05 ∗ 𝐷𝑖
𝑝𝑟𝑒 ≤ 𝑡𝑖                          ∀𝑖 ∈ 𝑇,     (3-5) 
        𝐷𝑖
𝑚𝑖𝑛 ≤ 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                 ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖
′,     (3-6) 
   𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                           ∀𝑖 ∈ 𝑅𝐼 , 𝑗 ∈ 𝑉𝑖
′,     (3-7) 
   𝑤𝑖 ≤ 𝑤
𝑚𝑎𝑥 .                                                                   (3-8) 
Step II 
Step II minimizes the mean dose to the hottest α%(MoHα) region of critical structures. The 
MoHα formulation computes the mean dose to the hottest α% by using the artificial variables p, 
z, and y in the formulation. The formulation of Step II is given by: 
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒                  𝐹𝐼𝐼(𝑤) =  ∑ (𝑦𝑖
𝛼 +
1
(1 − 𝛼)|𝑉𝑖
′|
∑ 𝑝𝑗𝑖
𝛼
|𝑉𝑖
′|
𝑗=1
)  ,                              
𝑖∈𝑅𝐼𝐼
 
     (3-9) 
𝑆𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜  
𝐷𝑗 − 𝑧𝑖𝑗 = 0                     ∀𝑖 ∈ 𝑅
𝐼𝐼 , 𝑗 ∈ 𝑉𝑖,    (3-10) 
𝑝𝑗𝑖
𝛼 ≥ 0 ,                                                             (3-11) 
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𝑝𝑗𝑖 + 𝑦𝑖
𝛼 − 𝑧𝑗𝑖 > 0          ∀𝑖 ∈ 𝑅
𝐼𝐼 , 𝑗 ∈ 𝑉𝑖,    (3-12) 
𝐹𝐼(𝑤) ≤ (1 + 𝑠) ∗ 𝐹𝐼(𝑤𝐼),                                         (3-13) 
𝐷𝑖
𝑚𝑖𝑛 ≤ 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥             ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖
′,    (3-14) 
𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                           ∀𝑖 ∈ 𝑅𝐼 , 𝑗 ∈ 𝑉𝑖
′,    (3-15) 
𝑤𝑖 ≤ 𝑤
𝑚𝑎𝑥.                                                                         (3-16) 
 
The objective function of the first step was allowed to degrade, by a small factor (1+s), as shown 
in equation    (3-13). The small factor was called slip, and the value of slip (1+s) was two.  Thus, 
slip effectively doubled the optimal value of the first step objective function. 
Step III 
The third step minimizes the average dose to normal structures while using constraints to 
preserve the result of the first and second steps. The optimization formulation is given by: 
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒                                    𝐹𝐼𝐼𝐼(𝑤) =  ∑
1
|𝑉𝑖|
∑ 𝐷𝑗(𝑤)
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼𝐼
 ,                                   
(3-17) 
𝑆𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜 
 
                       ∑ (𝑦𝑖
𝛼 +
1
(1 − 𝛼)|𝑉𝑖
′|
∑ 𝑝𝑗𝑖
𝛼
|𝑉𝑖
′|
𝑗=1
)
𝑖∈𝑅𝐼𝐼
≤ 𝑀𝛼
∗𝑖      ∀𝑖 ∈ 𝑅𝐼𝐼 , 
  (3-18) 
                                    𝐷𝑗 − 𝑧𝑖𝑗 = 0                                              ∀𝑖 ∈ 𝑅
𝐼𝐼 , 𝑗 ∈ 𝑉𝑖,   (3-19) 
𝑝𝑗𝑖
𝛼 ≥ 0,   (3-20) 
                                𝑝𝑗𝑖 + 𝑦𝑖
𝛼 − 𝑧𝑗𝑖 > 0                                         ∀𝑖 ∈ 𝑅
𝐼𝐼 , 𝑗 ∈ 𝑉𝑖,   (3-21) 
𝐹𝐼(𝑤) ≤ (1 + 𝑠)2 ∗ 𝐹𝐼(𝑤𝐼),                         (3-22) 
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                         𝐷𝑖
𝑚𝑖𝑛 ≤ 𝐷𝑗(w)  ≤ 𝐷𝑖
𝑚𝑎𝑥                           ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖,   (3-23) 
                          𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                                           ∀𝑖 ∈ 𝑅𝐼 , 𝑗 ∈ 𝑉𝑖,   (3-24) 
𝑤𝑖 ≤ 𝑤
𝑚𝑎𝑥.                                                        (3-25) 
 
Note that the result of the first step was preserved using constraints   (3-22) –   (3-24). The slip value was 
increased from (1+s) in the second step to (1+s)2 in the third. The equations     (2-18) to     (2-21) 
constrained the mean dose to the hottest α% region of the critical structure obtained in the second step. 
The optimal value of the mean dose to the hottest α% region of the critical structure is given by: 
𝑀𝛼
∗𝑖  = ∑ (𝑦𝑖
∗𝛼 +
1
(1 − 𝛼)|𝑉𝑖
′|
∑ 𝑝𝑗𝑖
∗𝛼
|𝑉𝑖
′|
𝑗=1
)     ∀𝑖 ∈ 𝑅𝐼𝐼
𝑖∈𝑅𝐼𝐼
 
(3-26) 
 
Step IV 
The fourth step smooths the beam profile to remove hot regions outside the target structures 
while preserving the result of the first, second and third steps. The optimization formulation is 
given by: 
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒                             𝐹𝐼𝑉(𝑤) =  ∑ 𝑤𝑖
2
𝑛
𝑖=1
,                                                                
          (3-27) 
𝑆𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜 
                          ∑ (𝑦𝑖
𝛼 +
1
(1 − 𝛼)|𝑉𝑖
′|
∑ 𝑝𝑗𝑖
𝛼
|𝑉𝑖
′|
𝑗=1
)
𝑖∈𝑅𝐼𝐼
≤ 𝑀𝛼
∗𝑖       ∀𝑖 ∈ 𝑅𝐼𝐼 , 
(3-28) 
                                        𝐷𝑗 − 𝑧𝑖𝑗 = 0                                                 ∀𝑖 ∈ 𝑅
𝐼𝐼 , 𝑗 ∈ 𝑉𝑖,          (3-29) 
                            𝑝𝑗𝑖
𝛼 ≥ 0,                                                                                           (3-30) 
                                𝑝𝑗𝑖 + 𝑦𝑖
𝛼 − 𝑧𝑗𝑖 > 0                                     ∀𝑖 ∈ 𝑅
𝐼𝐼 , 𝑗 ∈ 𝑉𝑖,          (3-31) 
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                                𝐹𝐼(𝑤) ≤ (1 + 𝑠)3 ∗ 𝐹𝐼(𝑤𝐼 ),                                                           (3-32) 
                           𝐷𝑖
𝑚𝑖𝑛 ≤ 𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                            ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖,          (3-33) 
                              𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥                                            ∀𝑖 ∈ 𝑅𝐼 , 𝑗 ∈ 𝑉𝑖,          (3-34) 
                               ∑
1
|𝑉𝑖|
∑ 𝐷𝑗(𝑤)
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼𝐼
≤ 𝑀𝐼𝐼𝐼
∗ ,                                                     
(3-35) 
𝑤𝑖 ≤ 𝑤
𝑚𝑎𝑥 .                                                       (3-36) 
 
Constraints (3-28) to (3-34) were the same as that used in the third step to preserve the result of 
the first and second steps. The only difference is in the slip value, and the slip was increased 
from (1+s)2 in the third step to (1+s)3 in the fourth. The equation (3-35) constrained the optimal 
value of the mean dose to the normal structure obtained in the third step. The optimal value of 
the third step is denoted by 𝑀𝐼𝐼𝐼
∗ . Mathematically, 
𝑀𝐼𝐼𝐼
∗  = ∑
1
|𝑉𝑖|
∑ 𝐷𝑗(𝑤 ∗)
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼𝐼
 
  (3-37) 
 
3.4 Improving the Performance of the Application 
The performance of the treatment planning optimization module was improved using the 
following two methods: 
Storage and access of the influence matrix: We analyzed the memory access pattern of the 
influence matrix and optimized the memory access pattern to reduce the application run time. 
Computing the exact Hessian matrix: We computed the exact Hessian matrix of the optimization 
model that reduced the application run time. 
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3.4.1 Storage and Access of the Influence Matrix 
Figure 3-2 shows the memory hierarchy in the computer system. Both memory size and  access 
time increase as we move further away from the processor. Memory and hard disk access time 
are around 50 and 1012 times larger (respectively) than that of cache access time[77]. Cache sizes 
typically range from kilobytes to megabytes; memory size is a few gigabytes, and the hard disk 
size is in terabytes. In our system, the L1 cache was 64KB, the L2 cache was 256KB and the L3 
cache was 8192KB. When the processor requires an item, it searches the cache. If the item is in 
the cache, then it is referred to as a cache “hit” and the requested item is served from the cache. 
On the other hand, if the item is not in the cache then it would be a cache “miss,” and the 
requested item is served from the lower level memory in the hierarchy. If there are many cache 
misses, the performance of the system is severely impaired, as it requires significantly more time 
to access an item from a lower level memory in the hierarchy. 
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Size     64 KB                256 KB                   2-4 MB                    4-16 GB                      4-16 TB 
Time     1ns                    3-10 ns                  10-20 ns                     50-100 ns                   5-10 ms 
Figure 3-2 Organization of a typical computer memory pipeline. The size and access time of memory (ns, 
nanoseconds; ms, milliseconds) increases as we move further away from the processor.  
 
We used the uBlas[97] library for matrix operations and stored the matrix in row-major order. 
Row-major ordering stores each row of the matrix end-to-end in memory. We accessed the 
influence matrix in two different ways: row- and column-wise to study the impact of the memory 
access pattern on the performance of the treatment planning application. In row-wise access, we 
accessed one row at a time, while in column-wise access, we accessed one column at a time. 
3.5 Computation of Hessian Matrix 
IPOPT[96] is a general purpose interior point optimization solver. The algorithm starts with 
some initial guess and computes the search direction based on gradient and second derivative 
(Hessian) information to find the next point in the iteration. 
In more detail, given the optimization problem 
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𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒   𝑓(𝑥)                               ∀𝑥𝜖𝑅𝑛, 
𝑆𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜  
                              𝑐(𝑥) = 0, 
                               𝑥 ≥ 0. 
 
                (3-38) 
 
The Lagrangian function is defined as  
 L(x,y,z) = f(x) + λ c(x) + z x, 
 are Lagrange multipliers for the equality constraints c(x) and the bound 
constraints x ≥ 0, respectively. 
Let (xk,λk,zk) be the current solution at some iteration "k. " The IPOPT solves the following 
equation to find the search direction: 
[
𝑊𝑘     𝐴𝑘   − 𝐼
𝐴𝑘
𝑇       0         0
𝑍𝑘      0        𝑋𝑘
] = − [
∇𝑓(𝑥𝑘) + 𝐴𝑘𝜆𝑘 − 𝑧𝑘
𝑐(𝑥𝑘)
𝑋𝑘𝑍𝑘𝑒 − 𝜇𝑗𝑒
] 
 
                             (3-39) 
Ak = , Wk = is Hessian of the Lagrangian function L(xk,λk,zk), and Xk = diag(xk). 
We solved the hierarchical optimization problem using both the quasi-Newton and Newton 
methods and recorded the run time of the application. In the quasi-Newton method, the IPOPT 
automatically approximates the Hessian matrix from the Jacobian matrix, whereas in Newton’s 
method, the user is required to provide the exact Hessian matrix.  
3.6 Experimental Results 
We compared the run times when the influence matrix was accessed in two different ways: row- 
and column-wise. Table 3-1 shows run time for row- vs. column-wise access of the influence 
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matrix. Compared with column-wise access, the row-wise access of the influence matrix reduced 
run time by an average factor of 400. Column-wise access means a full beamlet set is mixed with 
many regions of interest (ROIs), whereas row-wise access results in the ability to compute the full 
dose to a given ROI after loading only a fraction of the influence matrix. As discussed [77], 
modern processors use spatial locality to increase the probability of a cache hit. Spatial locality is 
based on the idea that a program is more likely to access memory locations close to the currently 
accessed location in the near future. In our implementation, the column-wise access incurred 
more cache misses than those incurred by the row-wise access.  
Table 3-1 Impact of row-wise and column-wise access of the influence matrix on the run time of the 
treatment planning application. We accessed the influence matrix one row at a time in row-wise access, 
and one column at a time in column-wise access. 
 
We observed that the IPOPT solver was faster when the exact Hessian matrix was used instead 
of an approximation. The IPOPT solver needs a second order derivative of the Lagrange 
function, which can either be approximated or evaluated by a user. Figure 3-3 shows the run 
times when the exact or the approximate Hessian matrices were used in the IPOPT solver. Our 
observation indicates that the IPOPT solver took a large number of iterations when the Hessian 
matrix was approximated (Table 3-2). Consequently, the IPOPT was four times faster when the 
Hessian matrix was exact compared with an approximation. The Quasi-Newton method made a 
 Time (minutes)  
Plan Column-wise Access Row-wise Access  Speedup 
1 583.99 1.26 462.9 
2 423.10 1.08 389.98 
3 121.59 0.19 639.59 
4 509.06 1.66 306.40 
5 538.66 1.36 393.44 
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small improvement in the objective function after a few optimization iterations (Figure 3-4). We 
studied the impact of prematurely terminating the optimization formulation on the dose 
distribution of treatment plans. We set the maximum number of iterations to 22 for the Quasi-
Newton and solved the optimization problem. e) Dose volume histogram of plan number 4 
 f) Dose volume histogram of plan number 5 
Figure 3-5 shows that the prematurely terminating optimization sacrificed the dose distribution to 
structures. We therefore computed the exact Hessian matrix of the optimization problem and 
provided it to the IPOPT solver. The exact Hessian matrix reduced the number of iterations in 
the optimization thus reducing the run time of the application. 
Table 3-2: Number of iterations required for the optimization using the Quasi-Newton and Newton 
methods. The Quasi-Newton method made a smaller improvement in the objective function after a few 
iterations and didn’t terminate, even after running the optimization for the maximum number of iterations.  
 
 
 
 
 
 
 
 
 
 Number of Iterations 
Plan Quasi-Newton Newton  
1 3000 28 
2 3000 38 
3 3000 28 
4 3000 29 
5 3000 60 
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Figure 3-3 Optimization time using Newton vs. Quasi-Newton method. 
                         
  
Figure 3-4 Convergence of Newton vs. Quasi-Newton method. The Quasi-Newton method made a small 
improvement in the objective function after a few iterations.  
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a) Dose volume histogram of plan number 1 b) Dose volume histogram of plan number 2  
         
c) Dose volume histogram of plan number 3  d) Dose volume histogram of plan number 3 
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e) Dose volume histogram of plan number 4  f) Dose volume histogram of plan number 5 
Figure 3-5 Dose-volume histogram demonstrating the effect of prematurely terminating the Quasi-
Newton optimization. We set the maximum number of optimization iterations to 22 for the Quasi-Newton 
method based on Figure 3-4. It is impossible to predetermine the number of optimization iterations that 
produces good dose distribution for all treatment plans.  
 
  
PTV 
Spinal Cord Spinal Cord 
PTV 
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We compared the dose quality and run time of the IPOPT-based treatment planning application 
with the Mosek-based treatment planning application developed by Clark et. al.[88]. Figure 3-6 
shows the dose-volume histograms (DVHs) and Figure 3-7 shows the dose color wash of head 
and neck treatment plans computed using the Mosek[98] and IPOPT solvers. Although there 
were a number of structures included in the optimization, we chose to show only a few of them 
in the histogram for the sake of clarity. The x-axis shows the dose distribution to the organs and 
the y-axis shows the fractional volume that received the specified dose. The dose distribution 
produced with the IPOPT solver (solid line) overlapped with that produced using the Mosek 
solver (dashed line) for each structure, indicating that both solvers produced nearly identical dose 
distributions.  
Figure 3-8 demonstrates the step-by-step change in the dose distribution to structures using 
hierarchical optimization. In our formulation, we optimized dose to the target structure in the 
first step, the dose to the brainstem in the second and the dose to the spinal cord in the third . The 
target dose was allowed to deteriorate by a "slip" factor in each step. Therefore, the target DVH 
deteriorates in each step, compared to the previous step, as shown in Figure 3-8.The DVH of the 
brainstem and spinal cord were better after the second and third step of the optimization, 
respectively.  
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a) Dose volume histogram of plan number 1  b) Dose volume histogram of plan number 2 
     
c) Dose volume histogram of plan number 3 
Figure 3-6 Dose-volume histogram (DVH)  produced in intensity-modulated radiation therapy treatment 
plans for a patient with head and neck cancer, optimized using the IPOPT-based (solid line) and Mosek-
based (dashed line) treatment planning applications. We chose to show three out of seven treatment plans 
as the other plans have the same DVH pattern.  
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Plan           IPOPT Plan          Mosek Plan 
 
  
 
1 
    
72.4 
 
 
 
 
 
 
 
0 
 
2 
 
 
 
74 
 
 
 
 
0 
 
 
 
 
3 
  
 
72.9 
Figure 3-7 Dose color wash showing the similarity of treatment plans produced by the IPOPT and Mosek 
solvers. We chose to show three out of seven head and neck treatment plans as the other plans have the 
same dose color wash pattern.   
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Figure 3-8 The dose-volume histogram (DVH) of the Planning Target Volume (PTV), Brainstem, and 
Spinal Cord produced in hierarchical optimization of three head and neck treatment plans. The 
optimization was solved using the IPOPT solver. We have optimized the dose to PTV in the first step, to 
the brainstem in the second and to the spinal cord in the third. The DVH shows that PTV coverage in the 
fourth step was less than that in the first. Low coverage was due to the "slip" parameter used in later 
optimization steps to relax the PTV dose constraints.  
Planning Target Volume Brainstem Spinal Cord 
1 
2 
3 
Plan 
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Table 3-3 shows the run times for IMRT optimization using either the IPOPT- or Mosek-based 
solvers for the seven head and neck plans. With a median increase in speed by a factor of 21, the 
IPOPT-based application was significantly faster than the Mosek-based application. 
 
Table 3-3. Run time of the IPOPT- and Mosek-based prioritized optimization.  
 
3.7 Discussion and Conclusion 
We studied the memory access pattern of the influence matrix and demonstrated that optimized 
access could significantly reduce the IMRT optimization time.  
We developed an efficient, open-source, and flexible treatment planning application, using 
hierarchical optimization, which automates IMRT treatment planning. Therefore, the application 
can find the best treatment plan in a single run without manual intervention. Moreover, the 
application is integrated with the CERR, a commonly used open-source tool for importing, 
contouring, and viewing treatment plans, which performs dose-volume and dose-surface 
 Time (minutes)  
Plan IPOPT-based Application Mosek-based Application Speedup 
1 17.39 356.65 20.5 
2 12.63 220.74 17.47 
3 7.51 164.84 21.92 
4 14.74 223.69 15.16 
5 16.08 379.15 23.57 
6 9.93 319.59 32.16 
7 14.31 934.18 65.25 
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analysis. Therefore, the application provides a complete suite for the treatment planning process.  
Finally, the open source model will allow new optimization models with minimal modifications. 
A user can provide model-specific information to include the new model and can reuse the built-
in hooks to manage communication between the CERR and the IPOPT solver. 
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Chapter 4: A Comparative Study of 
Hierarchical and Eclipse Treatment 
Planning Systems 
 
In chapter 3, we demonstrated that the Interior Point Optimizer (IPOPT) can be used to solve the 
nonlinear constrained hierarchical optimization formulation. In this chapter, we formulate the 
mathematical model to automate the treatment planning process and use the IPOPT solver to 
solve the optimization formulation.  
4.1 Introduction 
The dose-volume histogram (DVH) relates radiation dose to the volume of a structure[99]. The 
dose-volume metrics are based on the dose-volume histogram and are standard metrics used in 
clinics to evaluate the treatment plan. The commonly used dose-volume metrics are the dose 
received by x% volume of a structure (Dx), and the dose to at least x% volume of a structure 
(Vx). Although physicians and treatment planners widely use dose-volume metrics, these metrics 
can’t be directly used in the optimization formulation because they are non-convex and the 
optimization formulation based on the dose-volume metrics has multiple local minima[100]–
[103]. Therefore, the linear and quadratic surrogate functions are used to preserve the convexity 
of the IMRT optimization formulation. 
The commercial treatment planning system uses the weighted sum of the linear and quadratic 
functions to optimize the dose distribution. The weighted sum optimization formulation requires 
trial-and-error iterations to find the best trade-off in dose distribution. Hierarchical optimization 
was proposed to eliminate trial-and-error iterations in the treatment planning process. The 
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previous study demonstrated that hierarchical optimization can be used to automate the treatment 
planning process[72], [88]. However, these studies didn’t prepare the treatment plans in a clinical 
setting. It is essential to prepare the treatment plans using clinical criteria to demonstrate the 
potential of hierarchical optimization. Therefore, we automatically prepared treatment plans 
using hierarchical optimization in a clinical setting. We found that the linear and quadratic 
models were not enough to automatically produce treatment plans. Therefore, we proposed a 
nonlinear optimization formulation to automate the treatment planning process. We trained the 
model in six prostate plans and tested it in 25 prostate plans randomly selected from prostate 
patients treated at Memorial Sloan Kettering Cancer Center (MSK). Finally, we compared the 
automatically produced plans with the plans produced by the planners at MSK using the Eclipse 
treatment planning system.  
4.2 Methods  
We randomly selected 31 prostate patients treated at MSK to prepare treatment plans using the 
hierarchical optimization model. The hierarchical optimization model was trained in six prostate 
plans and tested in 25 plans.  
4.2.1 Application Work Flow 
Figure 4-1 shows the flow diagram of the automated treatment planning process based on 
hierarchical optimization. Treatment plans were exported from the Eclipse treatment planning 
system in the Digital Imaging and Communications in Medicine (DICOM) format and imported 
into the Computational Environment for Radiotherapy Research (CERR). The beam geometry 
and the contours of structures are obtained from the imported plan. The new beams were created 
in CERR interface using the beam geometry obtained from the imported plan, and the dose was 
calculated using the the voxel-based Monte Carlo (VMC++) dose calculation engine. The 
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hierarchical optimization was run based on the clinical criteria specified by the physicist of 
Memorial Sloan Kettering Cancer Center. The Monte Carlo dose calculation engine doesn’t 
incorporate the machine parameters and, therefore, the dose distribution of the hierarchical 
optimization was an ideal dose distribution. The ideal fluence map was exported from the CERR, 
imported into the Eclipse application, and the dose was calculated using the Eclipse dose 
calculation engine to incorporate the machine parameters. Dose distribution was deteriorated by 
incorporating the machine parameters. Therefore, the plan was re-optimized to prepare the final 
deliverable plan. 
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Figure 4-1 The flowchart of the automated treatment planning system. We exported treatment plans from 
the Eclipse treatment planning system and imported them into CERR. The first round of optimization 
used the voxel-based Monte Carlo (VMC++) dose calculation engine. Therefore, dose distribution was 
ideal. The second round of optimization incorporated the machine parameters and produced the 
deliverable dose distribution.  
4.2.2 Dose calculation 
We used the voxel-based Monte Carlo (VMC++) application to calculate the dose to the 
structures. VMC++[104] is an open source Monte Carlo[105] dose calculation engine and the 
CERR provides the interface to set the parameters for the VMC++ application. The VMC++ 
Stop 
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No 
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takes substantial time to calculate the dose and, therefore, the dose computation time was 
reduced by calculating the dose in parallel. The procedure Parallel-Dose-Computation takes the 
parameter IM, which contains beam information and the parameters for the VMC++ algorithm. 
The new structure "vmcparam" and "beams" were created to store beam information of each 
beam separately. The computation of each beam was carried out in parallel, but the computations 
of the beams’ beamlets were carried out sequentially.  
Algorithm 4-1 Pseudocode of dose computation in parallel 
Parallel-Dose-Computation(IM) 
1. vmcparam = Create a structure of size equals to the number of beams(beaminfo.length) 
2. beams = IM.beam 
3. for i=1 to beaminfo.length 
4. vmcparam(i).number_of_particles = IM.vmcparam(i).number_of_particles 
5. Vmcparam(i).number_of_batches = IM.vmcparam(i).number_of_batches 
6. parfor i=1 to beaminfo.length 
7. for j=1 to beams(i).numbeamlet 
8. dosefile = dosefile_beam_i_beamlet_j 
9. Vmc++(beams(i),vmcparam(i),dosefile) 
10. dose = Readdosefile(dosefile) 
11. beams(i).beamlets(j) = dose 
 
 
Dose calculation requires some parameters, namely voxel size, the parameters for the VMC++ 
algorithm, and beam geometry information. The voxel size was approximately 0.2 by 0.2 by 0.2 
cm in x, y and z directions and there were 256 slices in x and ydirections. Table 4-1 shows the 
parameters for the VMC++ algorithm. The parameter value can be set from graphical user 
interface (GUI) of the CERR application. The default value was used for the parameters that are 
not shown in Table 4-1. Finally, Table 4-2 shows the beam parameters. We used photon beam 
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size 0.2 by 0.5 cm to calculate the dose. The beam parameters were the same as that used by the 
planner at MSK to prepare treatment plans.   
Table 4-1 The parameter for the VMC++ algorithm. The parameters can be set using the CERR graphical 
user interface (GUI) interface. 
S.No. Parameters Name Values 
1.  Number of particles 50,000 
2.  Number of batches 10 
3.  Score dose to water Yes 
4.  Scatter method Exponential 
5.  Skip 1 
6.  Dimension 60 
7.  Skip 1 
8.  Dose term Gauss primary and 
scatter 
9.  Cut-off distance 4 
10.  Random step 30 
 
Table 4-2 The parameters for the beams used in dose calculation. The beam parameters were the same as 
those used by the planners at Memorial Sloan Kettering Cancer Center to prepare treatment plans. 
S.No. Parameters Name Values 
1.  Beam Modality Photons 
2.  Beam energy 15 MV 
3.  Beam delta x 0.25 
4.  Beam delta y 0.5 
4.2.3 Clinical criteria for treatment plans 
The clinical criteria used in hierarchical optimization were the same as those used by the planner 
at MSK to prepare treatment plans. The criteria specify the dose requirement to target and 
normal structures (Table 4-3). The target prescription dose was 72Gy and the dose to 95% of the 
target structure must equal the prescription dose. 53% volume of the rectum and bladder must 
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receive less than 47Gy of the dose. Similarly, the maximum dose to the rectum and bladder must 
be less than 103% and 105% of the prescription dose.  
Table 4-3 Clinical criteria used in hierarchical optimization. The criteria specify the dose requirement of 
the prostate plan. The target dose is given at the top rows of the table. The prescription dose was 72Gy 
and the rectum and bladder must satisfy dose-volume constraints. The criteria have been used to treat 
patients at Memorial Sloan Kettering Cancer Center.  
 
 
 
 
 
 
 
 
 
 
Prostate 
7200cGy 
 
 Target Criteria  
PTV D95% ~ 100% Cases with large amount of bladder-PTV overlap may 
result in somewhat inferior coverage PTV V95% ≥ 99% 
PTV Dmax ≤ 110% 
PTV Dmin near 100% 
Normal Tissue Criteria 
Structures Total Dose or 
Volume ≤ 
To: Comments 
Rectal Wall 53% of total 
volume 
V47Gy  
103.5% Max Point Dose Avoid hot spots 
in the rectal 
wall 
Rectoe** 103.5% Max Point Dose **one needs to 
look at this 
specifically for 
nodal cases 
Bladder Wall 53%(63%) of 
total volume 
V47Gy *Planner should 
first try to meet 
the V47Gy ≤ 
53%. If this is 
not possible a 
value of 63% 
may be used 
 105%(108%) Max point dose Avoid hot spots 
in the bladder 
wall 
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Femoral Heads 68Gy Max Point Dose  
 
4.2.4 Optimization Formulation 
Hierarchical optimization assigns priority to optimization goals and solves the goals based on the 
assigned priority. Table 4-4 shows the goals of hierarchical optimization and the priority of each 
goal. The target structure is in priority level 1; the rectum is in priority level 2, and the bladder 
and femur are in priority level 3. Moreover, the rectum and bladder hard constraints are in 
priority level 1, achieving good dose fall-off is in priority level 4, producing a smooth beam 
profile is in priority level 5, and incorporating the deliverability issue is in priority level 6. 
Hierarchical optimization has six steps corresponding to the six priority levels. Higher priority 
goals are optimized before lower priority goals. After optimizing higher priority goals, they are 
converted into constraints and lower priority goals are optimized in the presence of higher 
priority goal constraints.   
Table 4-4 The optimization goals and their priorities. Goals are optimized based on the assigned priority. 
Priority level one goals are optimized in the first step, priority level two goals are optimized in the second 
step and so on.   
S.No. Goals Priority Level 
1.  PTV D95% ~ 100% 1 
2.  Max point dose in rectum ≤ 
103.5% 
1 
3.  Max point dose in bladder ≤ 108% 1 
4.  V47Gy of rectum ≤ 53% of total 
volume 
2 
5.  V47Gy of bladder ≤ 53% of total 
volume 
3 
6.  Max point dose in Femoral Heads 3 
7.  Dose should fall-off outside the 4 
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target 
8.  Beamlet should be smooth 5 
9.  Incorporate the deliverability issue 6 
 
We have formulated the mathematical model needed to automate the treatment planning process 
using the hierarchical optimization framework. The optimization has six steps as discussed 
below. 
Step 1 
The first step optimizes the three highest priority goals as shown in Table 4-4. The first goal was 
to achieve the dose to 95% of the target structure as close as the 100% of the prescription dose. 
The objective function (4-1) minimizes the difference between the actual and prescribed dose. 
The variable "t," in the objective function, penalized the under-dose region in the target structure. 
The two other goals specify the maximum dose to the bladder and rectum and maximum dose 
constraints (4-3) were used to achieve the goal.  
Let T be the set of target structures, RI is the set of the normal structures, 𝐷𝑖
𝑝𝑟𝑒
 be the 
prescription dose to target structure i, Vi be the set of voxels in structure i, Dj is the dose to voxel 
j of a structure, then the first step formulation is given by: 
𝑴𝒊𝒏𝒊𝒎𝒊𝒛𝒆                                    ∑
1
|𝑉𝑖|
∑(𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2 + 𝑡𝑖
2
𝑗∈𝑉𝑖𝑖∈𝑇
,                                              
(4-1) 
𝑺𝒖𝒃𝒋𝒆𝒄𝒕 𝒕𝒐: 
𝐷𝑗 − 𝐷
𝑝 ≤ 𝑡𝑖             ∀𝑗 ∈ 𝑉𝑖, 𝑖 ∈ 𝑇, (4-2)  
𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥              𝑖 ∈ 𝑅𝐼 , ∀𝑗 ∈ 𝑉𝑖, (4-3) 
𝐷𝑗(𝑤)  ≤ 𝐷𝑖
𝑚𝑎𝑥         ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖. (4-4) 
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Let A be the influence matrix, w be the beamlets weight vector, and n be the number of beamlets 
in the optimization, then the dose to voxel j of the target structure is given by: 
𝐷𝑗 = ∑ ∑ 𝐴𝑗𝑘
𝑛
𝑘=1
∗ 𝑤𝑘               ∀𝑖 ∈ 𝑇
𝑗∈𝑉𝑖
 
(4-5) 
Step 2 
The second step optimizes the rectal dose. The dose-volume constraint of the rectum requires 
that 53% rectal volume must receive less than the 47Gy of the dose. The dose-volume constraints 
cannot be incorporated directly into the optimization without losing the convexity of the 
problem. Therefore, we used the linear combination of the generalized equivalent uniform dose 
(gEUD) [106]–[110] and the mean rectal dose  to enforce the dose-volume constraint to the 
rectum. The gEUD has a parameter called "a" and the parameter can be tuned to emphasize the 
high dose region of the rectum. Therefore, the rectum high dose region was controlled by the 
gEUD with a large "a" value and the low dose region was controlled by the mean dose. The 
objective function of the second step is given by: 
𝛾 ∗ 𝑔𝐸𝑈𝐷(𝑎) 𝑜𝑓 𝑡ℎ𝑒 𝑟𝑒𝑐𝑡𝑢𝑚 + 𝜌 ∗ 𝑚𝑒𝑎𝑛 𝑑𝑜𝑠𝑒 𝑡𝑜 𝑟𝑒𝑐𝑡𝑢𝑚 (4-6) 
𝛾, 𝑎, 𝑎𝑛𝑑 𝜌 are the model’s parameters, which we empirically determined the value of by training 
the model in the six training prostate plans (Table 4-5).  
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Table 4-5 The value of the model parameters for step 2. The parameter value was determined by 
training the model in the six prostate cases.  
Parameter Value 
a 20 
𝛾 0.5 
𝜌 0.5 
 
Let RII be the set of structure in the second step, Vi be the set of voxels of the structure i, Dj be 
the dose to the voxel j, then the second step formulation is given by: 
𝑴𝒊𝒏𝒊𝒎𝒊𝒛𝒆   0.5 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑅𝐼𝐼
+ 0.5 ∗ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗 ,
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼
 
   (4-7) 
 
𝑺𝒖𝒃𝒋𝒆𝒄𝒕 𝒕𝒐: 
∑ min (0, 𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
≤ ∑ min (0, 𝐷𝑗
𝐼 − 𝐷𝑖
𝑝𝑟𝑒)2        ∀𝑖 ∈ 𝑇
𝑗∈𝑉𝑖
, 𝑗 ∈ 𝑉𝑖,  
   (4-8) 
1
|𝑉𝑖|
∑(𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
≤ 𝑠 ∗
1
|𝑉𝑖|
∑(𝐷𝑗
𝐼 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
      ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖, 
 (4-9) 
𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥              𝑖 ∈ 𝑇, ∀𝑗 ∈ 𝑉𝑖,  (4-10) 
𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥              𝑖 ∈ 𝑅𝐼 , ∀𝑗 ∈ 𝑉𝑖.  (4-11)  
 The dose to jth voxel of the rectum Dj is given by: 
𝐷𝑗 = ∑ ∑ 𝐴𝑗𝑘
𝑛
𝑘=1
∗ 𝑤𝑘               ∀𝑖 ∈ 𝑅
𝐼𝐼
𝑗∈𝑉𝑖
 
(4-12) 
Similarly, Let wI be the beamlet weight found in the first step, then the first step dose to the 
voxel j of the target structure (𝐷𝑗
𝐼) is given by: 
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𝐷𝑗
𝐼 = ∑ ∑ 𝐴𝑗𝑘
𝑛
𝑘=1
∗ 𝑤𝑘
𝐼                ∀𝑖 ∈ 𝑅𝐼𝐼
𝑗∈𝑉𝑖
 
(4-13) 
The result of the first step should be preserved while optimizing for the second step goals. The 
target dose of the first step was preserved by using constraints  (4-9) and  (4-10). However, the 
rectal dose cannot be reduced if the hard constraint is used to preserve the target dose. Therefore, 
we applied a slip in constraint  (4-9) to relax the target dose. Compared to the plan produced by 
the planner, the hierarchical system plan had lower D95 to the target structure when a large slip 
was used and a higher dose in the rectum when the smaller slip was used. We noticed that the 
planner tends to sacrifice the homogeneity of the target dose to improve on the rectal dose. 
Therefore, we introduced constraint    (4-8) to preserve the sum of the dose to the target voxels 
that was less than the prescription dose. Constraint    (4-8) ensured that no substantial cold spots 
were introduced to the target structure in the second step. This enabled us to use a large slip to 
reduce the rectal dose while not degrading the D95 to the target structure.  
Step 3 
The third step optimizes the bladder dose under the constraints to preserve the previous step’s 
result and to limit the maximum dose to the femur. The clinical criteria state that the maximum 
dose to the femur must be less than 68Gy and the dose to 53% volume of the bladder must be 
less than 47Gy. The objective function of the third step minimizes the linear combination of the 
gEUD and the mean dose to the bladder. Mathematically, 
𝛾 ∗ 𝑔𝐸𝑈𝐷(𝑎) 𝑜𝑓 𝑡ℎ𝑒 𝑏𝑙𝑎𝑑𝑑𝑒𝑟 + 𝜌 ∗ 𝑚𝑒𝑎𝑛 𝑑𝑜𝑠𝑒 𝑡𝑜 𝑡ℎ𝑒 𝑏𝑙𝑎𝑑𝑑𝑒𝑟 
γ, a and ρ are the model’s parameters, which were empirically determined by training the model 
in the six prostate plans. The table below shows the value of the model parameters: 
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Table 4-6 The value of the model parameters of step 3. The parameter value was determined by training 
the model in the six prostate cases. 
Parameter Value 
a 20 
𝛾 0.9 
𝜌 0.1 
 
Let Rb and Rf be the bladder and femur structures that are being optimized in the third step, then 
the optimization formulation is given by: 
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𝑴𝒊𝒏𝒊𝒎𝒊𝒛𝒆   0.9 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑎
𝑗∈𝑉𝑖 )
1
𝑎⁄
𝑖∈𝑅𝑏 + 0.1 ∗
1
|𝑉𝑖|
⁄ ∑ ∑ 𝐷𝑗𝑗∈𝑉𝑖𝑖∈𝑅𝑏 , 
(4-14) 
 𝑺𝒖𝒃𝒋𝒆𝒄𝒕 𝒕𝒐:                            𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥                      ∀𝑖 ∈ 𝑅𝑓 , 𝑗 ∈ 𝑉𝑖,                (4-15) 
0.5 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑅𝐼𝐼
+ 0.5 ∗ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼
≤  0.5 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝐼𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑅𝐼𝐼
+ 0.5 ∗ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝐼
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼
, 
 
(4-16) 
∑ min (0, 𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
≤ ∑ min (0, 𝐷𝑗
𝐼 − 𝐷𝑖
𝑝𝑟𝑒)2        ∀𝑖 ∈ 𝑇
𝑗∈𝑉𝑖
, 𝑗 ∈ 𝑉𝑖, 
 
(4-17) 
1
|𝑉𝑖|
∑(𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
≤  𝑠2 ∗
1
|𝑉𝑖|
∑(𝐷𝑗
𝐼 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
      ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖, 
(4-18) 
𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥              𝑖 ∈ 𝑇, ∀𝑗 ∈ 𝑉𝑖, (4-19) 
𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥             𝑖 ∈ 𝑅𝐼 , ∀𝑗 ∈ 𝑉𝑖.   (4-20) 
 
Note that constraint (4-16) preserves the rectal dose, constraints (4-17), (4-18) and (4-19) 
preserve the target dose and constraint   (4-20) limits the maximum dose in the bladder and 
rectum. 
Step 4 
The goal of step 4 was to squash the hot spot outside the target structure and produce good dose 
falloff. We created two new structures: rind, which encompass the region 2cm away from the 
target structure and rind’, which encompasses the region 2cm within the target structure. The 
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fourth step’ s objective function minimizes the general equivalent uniform dose (gEUD) to rind 
and gEUD and the mean-square dose to the rind’ structure. The rind and rind’ include all the 
voxels in the patient scan. Therefore, we down-sampled the rind and rind’ structures by a 
sampling rate of 2 to make the optimization computationally feasible.  
The hot spot outside the target structure could not be squashed by only minimizing the objective 
function of the rind structure. The constraints to preserve the bladder dose forbid the squashing 
of all the hot spots outside the target structure. The bladder mean dose must be allowed to 
increase in order to squash the hot spot outside the target structure. However, we didn’t know the 
minimum increase in the bladder dose needed to squash all the hot spots. Therefore, we 
introduced a variable epsilon "ϵ" in the objective and constraint for the bladder term. The 
optimizer determines the minimum increase in the bladder mean dose needed to squash all the 
hot spots outside the target structure.  
The gEUD and the mean-square dose term should be scaled to the same magnitude. We 
calculated the gEUD and mean-square dose using the third step result and divided the gEUD by 
the mean-square dose to get the scaling factor ∅.  
Let 𝐷𝑗
𝐼𝐼𝐼 be the dose to the voxel j obtained in the third step, then the parameters’ value are 
calculated as follows: 
∅ =
∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝐼𝐼2
𝑗∈𝑉𝑖𝑖∈𝑟𝑖𝑛𝑑
∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝐼𝐼𝑎
𝑗∈𝑉𝑖 )
1
𝑎⁄
𝑖∈𝑟𝑖𝑛𝑑∪𝑟𝑖𝑛𝑑′
 
  (4-21) 
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𝑴𝒊𝒏𝒊𝒎𝒊𝒛𝒆:  ϵ + ∅ ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑟𝑖𝑛𝑑∪𝑟𝑖𝑛𝑑′
+ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
2,
𝑗∈𝑉𝑖𝑖∈𝑟𝑖𝑛𝑑′
 
 
 (4-22) 
 
𝑺𝒖𝒃𝒋𝒆𝒄𝒕 𝒕𝒐: 
∑ 1 |𝑉𝑖|
⁄ ∑ 𝐷𝑗
𝑗∈𝑉𝑖𝑖∈𝑅𝑏
≤ ∑ 1 |𝑉𝑖|
⁄ ∑ 𝐷𝑗
𝐼𝐼𝐼
𝑗∈𝑉𝑖𝑖∈𝑅𝑏
+ ϵ, (4-23) 
𝐷𝑗 ≤ 𝐷𝑖
𝐼𝐼𝐼𝑚𝑎𝑥              ∀𝑖 ∈ 𝑅𝑓 , ∀𝑗 ∈ 𝑉𝑖, (4-24) 
𝐷𝑗
𝑚𝑎𝑥 ≤ 𝐷𝑖
𝐼𝐼𝐼𝑚𝑎𝑥              ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑘, 𝑘 ∈ 𝑟𝑖𝑛𝑑
′, (4-25) 
0.5 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑅𝐼𝐼
+ 0.5 ∗ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼
≤  0.5 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝐼𝐼𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑅𝐼𝐼
+ 0.5 ∗ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝐼𝐼 ,
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼
 
(4-26) 
∑ min (0, 𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
≤ ∑ min (0, 𝐷𝑗
𝐼 − 𝐷𝑖
𝑝𝑟𝑒)2        ∀𝑖 ∈ 𝑇
𝑗∈𝑉𝑖
, 𝑗 ∈ 𝑉𝑖, 
 (4-27) 
 
1
|𝑉𝑖|
∑(𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
≤  𝑠3 ∗
1
|𝑉𝑖|
∑(𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
      ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖, 
(4-28) 
𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥              𝑖 ∈ 𝑇, ∀𝑗 ∈ 𝑉𝑖, (4-29) 
𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥             𝑖 ∈ 𝑅𝐼 , ∀𝑗 ∈ 𝑉𝑖.  (4-30) 
 
Constraints (4-31) to (4-32) are the same as those in step 3 formulation, and they are used to 
preserve the result of steps 1 and 2. Note that the slip value was increased from s2 to s3 to relax 
the target dose constraint. 
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Step 5 
Step 5 smooths the beam profile to produce the deliverable dose distribution. We applied a 
Laplacian smoothing function for this purpose. 
Let wi be the weight of the i
th beamlet, wi(xk,yk) be the beamlet at the (xk,yk) co-ordinate then the 
Laplacian smoothing is given by: 
𝐿𝑖(𝑤) =  −4𝑤𝑖(𝑥𝑘, 𝑦𝑘) + 𝑤𝑖+1(𝑥𝑘+1, 𝑦𝑘) + 𝑤𝑖+2(𝑥𝑘, 𝑦𝑘+1) + 𝑤𝑖+3(𝑥𝑘−1, 𝑦𝑘)
+ 𝑤𝑖+4(𝑥𝑘, 𝑦𝑘−1) 
     (4-33) 
If there are n beamlets, then the objective function is given by: 
𝑴𝒊𝒏𝒊𝒎𝒊𝒛𝒆                                    ∑ 𝐿𝑖(𝑤)
2𝑛
𝑖=1 ,    (4-34) 
𝑺𝒖𝒃𝒋𝒆𝒄𝒕 𝒕𝒐: 
 
 
∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
2
𝑗∈𝑉𝑖𝑖∈𝑟𝑖𝑛𝑑′
≤ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝑉2
𝑗∈𝑉𝑖
,
𝑖∈𝑟𝑖𝑛𝑑′
 
   (4-35) 
∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑟𝑖𝑛𝑑∪𝑟𝑖𝑛𝑑′
≤ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝑉𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
,
𝑖∈𝑟𝑖𝑛𝑑∪𝑟𝑖𝑛𝑑′
 
   (4-36) 
 
0.5 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑅𝐼𝐼
+ 0.5 ∗ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼
≤  0.5 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝑉
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑅𝐼𝐼
+ 0.5 ∗ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝐼𝑉 ,
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼
 
   (4-37) 
∑ min (0, 𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
≤ ∑ min (0, 𝐷𝑗
𝐼 − 𝐷𝑖
𝑝𝑟𝑒)2        ∀𝑖 ∈ 𝑇
𝑗∈𝑉𝑖
, 𝑗 ∈ 𝑉𝑖, 
    (4-38) 
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1
|𝑉𝑖|
∑(𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
≤  𝑠3 ∗
1
|𝑉𝑖|
∑(𝐷𝑗
𝐼 − 𝐷𝑖
𝑝𝑟𝑒)2
𝑗∈𝑉𝑖
      ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑖, 
   (4-39) 
𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥              𝑖 ∈ 𝑇, ∀𝑗 ∈ 𝑉𝑖,  (4-40) 
𝐷𝑗 ≤ 𝐷𝑖
𝑚𝑎𝑥              𝑖 ∈ 𝑅𝐼 , ∀𝑗 ∈ 𝑉𝑖,  (4-41) 
∑ 1 |𝑉𝑖|
⁄ ∑ 𝐷𝑗
𝑗∈𝑉𝑖𝑖∈𝑅𝑏
≤ ∑ 1 |𝑉𝑖|
⁄ ∑ 𝐷𝑗
𝐼𝑉,
𝑗∈𝑉𝑖𝑖∈𝑅𝑏
 
 (4-42) 
𝐷𝑗 ≤ 𝐷𝑖
𝐼𝑉𝑚𝑎𝑥              ∀𝑖 ∈ 𝑅𝑓 , ∀𝑗 ∈ 𝑉𝑖,  (4-43) 
𝐷𝑗 ≤ 𝐷𝑖
𝐼𝑉𝑚𝑎𝑥              ∀𝑖 ∈ 𝑇, 𝑗 ∈ 𝑉𝑘, 𝑘 ∈ 𝑟𝑖𝑛𝑑
′.  (4-44) 
Let Vi be the set of voxels of a structure i, then the dose to the voxel j (𝐷𝑗
𝐼𝑉) is given by: 
𝐷𝑗
𝐼𝑉 = ∑ ∑ 𝐴𝑗𝑘
𝑛
𝑘=1
∗ 𝑤𝑘
𝐼𝑉  ,              
𝑗∈𝑉𝑖
 
    (4-45) 
 
𝑤𝑘
𝐼𝑉 is the optimal beamlet weight found in the fourth step.  
 
Similarly, 𝐷𝑖
𝐼𝑉𝑚𝑎𝑥 is the maximum dose of a structure and is given by: 
𝐷𝑖
𝐼𝑉𝑚𝑎𝑥 = max {𝐷𝑗
𝐼𝑉: 𝑗 ∈ 𝑉𝑖} 
Step 6 
The CERR dose calculation algorithm does not take the deliverable parameters into 
consideration. The beam profile produced from step 5 was ideal, but the linear accelerator can't 
deliver it. Therefore, the beam profile was exported into text format from the CERR application 
and imported into the Eclipse treatment planning system. Finally, the dose was computed using 
the Eclipse dose calculation algorithm to produce the deliverable plans.  
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The dose distribution of treatment plans deteriorated when the dose was computed using the 
Eclipse dose calculation algorithm. The new hot and cold spots were introduced in the target 
structure and the dose to 95% of the target structure was substantially degraded. We introduced a 
new step in the optimization to correct the deteriorated dose distribution. The dose was corrected 
by assigning a new prescription dose to each voxel of the target structure. The prescription dose 
was decreased if the Eclipse system produced a higher dose than that of the hierarchical and 
increased otherwise.  
Let 𝐷𝑗
𝐸𝑐𝑙𝑖𝑝𝑠𝑒
 be the dose to the voxel j of the target structure after running through the Eclipse, 
and 𝐷𝑗
ℎ𝑖𝑒𝑟𝑎𝑟𝑐ℎ𝑖𝑐𝑎𝑙 be the dose to the voxel j of the target structure before running through the 
Eclipse, then the optimization formulation is given by: 
𝑴𝒊𝒏𝒊𝒎𝒊𝒛𝒆 ∑
1
|𝑉𝑖|
∑(𝐷𝑗 − 𝐷𝑖
𝑝𝑟𝑒 + 𝐷𝑗
𝐸𝑐𝑙𝑖𝑝𝑠𝑒 − 𝐷𝑗
ℎ𝑖𝑒𝑟𝑎𝑟𝑐ℎ𝑖𝑐𝑎𝑙)2
𝑗∈𝑉𝑖𝑖∈𝑇
, 
    (4-46) 
𝑺𝒖𝒃𝒋𝒆𝒄𝒕 𝒕𝒐 ∶ 
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∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
2
𝑗∈𝑉𝑖𝑖∈𝑟𝑖𝑛𝑑′
≤ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑉2 ,
𝑗∈𝑉𝑖𝑖∈𝑟𝑖𝑛𝑑′
 
 (4-47) 
∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑟𝑖𝑛𝑑∪𝑟𝑖𝑛𝑑′
≤ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑉𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
,
𝑖∈𝑟𝑖𝑛𝑑∪𝑟𝑖𝑛𝑑′
 
 (4-48) 
 ∑ 𝐿𝑖(𝑤)
2
𝑛
𝑖=1
≤  ∑ 𝐿𝑖(𝑤
𝑉)2
𝑛
𝑖=1
, 
 (4-49) 
0.8 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑅𝐼𝐼
+ 0.2 ∗ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼
≤  0.8 ∗ ∑ (1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑉𝑎
𝑗∈𝑉𝑖
)
1
𝑎⁄
𝑖∈𝑅𝐼𝐼
+ 0.2 ∗ ∑ 1 |𝑉𝑖|
⁄ ∗ ∑ 𝐷𝑗
𝑉 ,
𝑗∈𝑉𝑖𝑖∈𝑅𝐼𝐼
 
 (4-50) 
∑ 1 |𝑉𝑖|
⁄ ∑ 𝐷𝑗
𝑗∈𝑉𝑖𝑖∈𝑅𝑏
≤ ∑ 1 |𝑉𝑖|
⁄ ∑ 𝐷𝑗
𝑉 .
𝑗∈𝑉𝑖𝑖∈𝑅𝑏
 
 (4-51) 
 
Let wV be the optimal beamlet weight found in the fifth step, then the dose to voxel j obtained 
from the fifth step is given by: 
𝐷𝑗
𝑉 =  ∑ ∑ 𝐴𝑗𝑘
𝑛
𝑘=1
∗ 𝑤𝑘
𝑉                
𝑗∈𝑉𝑖
 
  (4-52) 
 
4.3 Results 
The hierarchical system produced the same or better quality treatment plans than those produced 
by the planner using the Eclipse treatment planning system. We randomly selected 31 prostate 
plans treated at MSK, trained the hierarchical model in six prostate plans, and tested the model in 
25 plans. The dose to 95% region (D95) of the target structure from the hierarchical system was 
scaled to match the D95 of the target structure obtained from the Eclipse treatment planning 
system (Figure 4-2 to Figure 4-7). The mean dose to the rectum and bladder were substantially 
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lower for the treatment plans prepared using the hierarchical system than that prepared using the 
Eclipse treatment planning system. The hierarchical system produced a 10% lower average mean 
dose to the rectum and bladder than that of the Eclipse treatment planning system in 31 prostate 
plans (Table 4-7,  
Table 4-11, Table 4-13). Similarly, the maximum dose to the rectum and bladder was almost 
same from both systems across all treatment plans ( 
 
Table 4-12 and  
 
 
Table 4-14). The result suggests that the hierarchical system could automatically produce dose 
distribution comparable with the treatment plans produced by the planner using the Eclipse 
treatment planning system. 
4.4 Training the Model 
We trained the model in six plans to determine the objective functions, constraints, and model 
parameters needed to produce treatment plans. The dose distribution from the hierarchical 
system was comparable or better than that of the Eclipse treatment planning system. The 
hierarchical system substantially reduced the dose in the rectum and bladder (Figure 4-2 to 
Figure 4-7). The rectal volume that receives at least 47Gy (V47) from the hierarchical system 
was almost 30% lower than that of the Eclipse system in three out of six training plans (Table 
4-7). The hierarchical system increased V47 by 0.05% in three plans, but the increase was 
negligibly small. Similarly, the bladder V47 from the hierarchical system was almost 11% lower 
on average than that from the Eclipse system in five out of six plans (Table 4-7). The target D95 
was the same from both systems because of scaling. The dose color-wash shows that no hot spot 
was produced outside the target structure and that the dose decreased as the distance from the 
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target structure increased. Therefore, the hierarchical model seems to produce treatment plans 
automatically without manual intervention. 
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Figure 4-2 Dose distribution of prostate treatment plan 2. a) Dose 
color-wash of the dose distribution obtained from hierarchical 
and Eclipse treatment planning systems. b) Dose-volume 
histogram of the structures in the optimization. 
82 
 
   
76.2 
0 
a) 
 
Eclipse 
 
 
 
 
 
 
 
 
 
 
 
Hierarchical 
 
 
    
   b)                                                                         
   
 
 
 
  
Figure 4-3 Dose distribution of prostate treatment plan 5. 
a) Dose color-wash of the dose distribution obtained   
from hierarchical and Eclipse treatment planning systems. 
b) Dose-volume histogram of the structures in the 
optimization. 
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Figure 4-4 Dose distribution of prostate treatment plan 
6. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems. b) Dose-volume histogram of the structures in 
the optimization. 
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Figure 4-5 Dose distribution of prostate treatment 
plan 7. a) Dose color-wash of the dose distribution 
obtained from hierarchical and Eclipse treatment 
planning systems.  b) Dose-volume histogram of the 
dose distribution obtained from hierarchical and 
Eclipse treatment planning systems. Dose-volume 
histogram of the structures in the optimization. 
85 
 
a) 
  
Eclipse 
 
77.3 
0 
 
 
Hierarchical 
 
 
   b)              
 
 
 
 
 
 
 
 
Figure 4-6 Dose distribution of prostate treatment plan 
8. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems. b) Dose-volume histogram of the structures in 
the optimization.  
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Figure 4-7 Dose distribution of prostate treatment plan 10. a) 
Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) Dose-
volume histogram of the structures in the optimization. 
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Table 4-7 The volume that receives at least 47Gy (V47) of the rectum and bladder of the hierarchical and 
Eclipse treatment plans. The hierarchical system produced the lower V47 in more treatment plans than 
that produced by the Eclipse treatment planning system. 
 
 
 
4.5 Testing the Model 
We prepared 25 prostate treatment plans using the hierarchical system to demonstrate the 
potential of hierarchical optimization to automate the treatment planning process. The treatment 
plans were evaluated using two different methods: 1) the hierarchical treatment plans were 
presented to the physicist of MSK, the physicist categorized the dose to target and normal 
structures into one of four categories: inferior, same, better and superior, based on their 
impression of the hierarchical and Eclipse plans, 2) the common dosimetry criteria were 
compared for treatment plans produced from the hierarchical and Eclipse treatment planning 
systems. 
Based on the physicist’s impression and the common dosimetry criteria, the target dose from the 
hierarchical system seems better than that of the Eclipse system in the majority of treatment 
plans. The target dose was inferior in three treatment plans, the same in 12, better in seven  and 
Plan 
Number 
Rectum V47 
of 
hierarchical 
plans in % 
(a) 
Rectum V47 
of  Eclipse 
plans in % 
(b) 
Ratio 
a/b 
Bladder 
V47 of 
hierarchical 
plans in % 
(c) 
Bladder 
V47 of 
Eclipse 
plans in % 
(d) 
Ratio  
c/d 
2 28.4  40 0.71 27.6 33.7 0.81 
5 52.85 52.56 1.005 21.19 24.67 0.85 
6 40.13 52.13 0.76 31.94 35.97 0.88 
7 51.98 50.89 1.02 36.55 38.04 0.96 
8 39.5 37.44 1.05 34 37.07 0.91 
10 42.64 56.48 0.75 70.37 63.88 1.10 
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superior in three (Table 4-8, Figure 4-2 to Figure 4-32). Table 4-9 and Table 4-10 show dose to 
99% of the target structure (D99), dose to 5% of the target structure (D05), and maximum and 
minimum dose to the target structure obtained from the hierarchical and Eclipse treatment 
planning systems. The average ratio of the D99 and D05 obtained from the hierarchical system to 
the Eclipse system was close to 1, suggesting that both systems produced the same target 
coverage. Similarly, the average ratio of the maximum dose to the target structure obtained from 
the hierarchical system to the Eclipse system was close to 1, suggesting that the maximum dose 
obtained from the hierarchical system was the same as that obtained from the Eclipse system. 
Finally, the minimum dose to the target structure obtained from the hierarchical system was 
almost 5% higher than that obtained from the Eclipse system. The higher minimum dose 
suggests that the hierarchical system didn’t produce any cold spots in the target structure. 
The rectal dose of the hierarchical system seems better than that of the Eclipse system in the 
majority of treatment plans. The rectal dose was inferior in four treatment plans, the same in 
four, better in six and superior in 11 (Table 4-8, Figure 4-2 to Figure 4-32).  
Table 4-11 shows the ratio between the rectum V47 of the hierarchical and Eclipse systems. The 
average ratio of V47 of the rectum was 0.87, suggesting that rectum V47 of the hierarchical 
system was lower than that of the Eclipse system. Similarly,  
 
Table 4-12 shows the ratio between the rectum maximum dose of the hierarchical and the 
Eclipse systems. The average ratio was 1, which implied that both systems produced the same 
maximum dose. Finally,  
 
Table 4-12 shows the ratio between the mean rectal dose of the hierarchical and Eclipse systems. 
The average ratio of the mean rectal dose was 0.91, suggesting that the mean rectal dose of the 
hierarchical system was lower than that of the Eclipse system. The physicist’s impression and the 
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dosimetry metrics supports that the rectal dose of the hierarchical system was better than that of 
the Eclipse treatment planning system. 
The bladder dose of the hierarchical system was substantially lower than that of the Eclipse 
treatment planning system. The bladder dose was inferior in one treatment plan, the same in 
three, better in 13 and superior in eight (Table 4-8) (Figure 4-2 to Figure 4-32). Table 4-13 
shows the ratio between the bladder V47 of the hierarchical and Eclipse systems. The average 
ratio of V47 of the bladder was 0.91, suggesting that bladder V47 of the hierarchical system was 
lower than that of the Eclipse system. Similarly, Table 4-14 shows the ratio between the bladder 
maximum dose of the hierarchical and Eclipse systems. The average ratio was 1, which implied 
that both systems produced the same maximum dose. Finally, Table 4-14 shows the ratio 
between the mean bladder dose of the hierarchical and Eclipse systems. The average ratio of the 
mean dose to the bladder was 0.92, suggesting that the bladder mean dose of the hierarchical 
system was lower than that of the Eclipse system. The result suggests that the bladder dose of the 
hierarchical system was better than that of the Eclipse treatment planning system. 
The clinical criteria require that the femur maximum dose must be less than 68Gy. The dose to 
femur obtained from the hierarchical system satisfied the maximum dose criteria (Table 4-15). 
However, the mean dose to the femur of the hierarchical system was almost 10% higher than that 
of the Eclipse system (Table 4-15). The femur was considered a lower priority structure in the 
optimization. Thus, the mean dose to the femur increased due to a decrease in the mean dose to 
the bladder and rectum. Nevertheless, the femur satisfied the maximum dose constraint. 
Table 4-8 Categorization of the dose to target and normal structure into one of four categories: inferior, 
same, better, and superior. Physicists from Memorial Sloan Kettering Cancer Center categorized dose 
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distribution into one of the four categories based on the overall impression of dose distribution of the 
treatment plans obtained from the hierarchical and Eclipse treatment planning systems. 
Plan Number Target Dose Rectum 
Dose 
Bladder Dose 
12 Superior Better  Same 
13 Same Superior Better 
15 Same Better Superior 
16 Same Inferior Better 
18 Superior Better Superior 
19 Superior Inferior Superior 
20 Same Same Better 
21 Same Superior Superior 
22 Same Superior Superior 
24 Better Better Better 
26 Same Inferior Better 
27 Better Superior Inferior 
28 Better Better Better 
29 Better Inferior Superior 
30 Better Superior Superior 
31 Same Same Better 
32 Inferior Superior Same 
33 Same Superior Superior 
34 Better Better Same 
35 Inferior Superior Better 
36 Better Same Better 
37 Same Superior Better 
38 Same Superior Better 
39 Same Superior Better 
40 Inferior Same Better 
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Figure 4-8 Dose distribution of prostate treatment plan 
12. a) Dose color-wash of the dose distribution 
obtained from hierarchical and Eclipse treatment 
planning systems. b)  Dose-volume histogram of the 
structures in the optimization. 
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Figure 4-9 Dose distribution of prostate treatment plan 13. a) 
Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) Dose-
volume histogram of the structures in the optimization. 
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Figure 4-10 Dose distribution of prostate treatment plan 
15. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning systems. 
b) Dose-volume histogram of the structures in the 
optimization. 
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Figure 4-11 Dose distribution of prostate treatment plan 16. a) 
Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) Dose-
volume histogram of the structures in the optimization. 
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Figure 4-12 Dose distribution of prostate treatment plan 18. 
a) Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) 
Dose-volume histogram of the structures in the optimization. 
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Figure 4-13 Dose distribution of prostate treatment plan 
19. a) Dose color-wash of the dose distribution 
obtained from hierarchical and Eclipse treatment 
planning systems. b) Dose-volume histogram of the 
structures in the optimization. 
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Figure 4-14 Dose distribution of prostate treatment plan 20. a) 
Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems.  ) Dose-
volume histogram of the structures in the optimization. 
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Figure 4-15 Dose distribution of prostate treatment plan 21.  ) 
Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) Dose-
volume histogram of the structures in the optimization. 
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Figure 4-16 Dose distribution of prostate treatment plan 
22. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems. b) Dose-volume histogram of the structures in 
the optimization. 
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Figure 4-17 Dose distribution of prostate treatment plan 24. 
a) Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems.  ) Dose-
volume histogram of the structures in the optimization. 
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Figure 4-18 Dose distribution of prostate treatment plan 26. a) 
Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) Dose-
volume histogram of the structures in the optimization. 
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Figure 4-19  Dose distribution of prostate treatment plan 27. a) 
Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) Dose-
volume histogram of the structures in the optimization. 
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Figure 4-20 Dose distribution of prostate treatment plan 
28. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning systems.   
) Dose-volume histogram of the structures in the 
optimization. 
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Figure 4-21 Dose distribution of prostate treatment plan 
29. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems. b) Dose-volume histogram of the structures in 
the optimization. 
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Figure 4-22 Dose distribution of prostate treatment plan 30. 
a) Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems.  ) 
Dose-volume histogram of the structures in the 
optimization. 
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Figure 4-23 Dose distribution of prostate treatment plan 
31. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems.    ) Dose-volume histogram of the structures in 
the optimization. 
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Figure 4-24 Dose distribution of prostate treatment plan 32. 
a) Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) 
Dose-volume histogram of the structures in the optimization. 
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Figure 4-25 Dose distribution of prostate treatment plan 33. 
a) Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems.  ) 
Dose-volume histogram of the structures in the optimization. 
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Figure 4-26 Dose distribution of prostate treatment plan 34. a) 
Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) Dose-
volume histogram of the structures in the optimization 
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Figure 4-27 Dose distribution of prostate treatment plan 
35. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems. b) Dose-volume histogram of the structures in 
the optimization. 
a) 
 
Eclipse 
 
77.6 
0 
 
 
Hierarchical 
 
 
 b)  
 
 
 
 
 
    
 
 
    
 
111 
 
a) 
 
Eclipse 
 
77.6 
0 
 
 
Hierarchical 
 
   
 b)    
                     
  
 
 
 
 
 
 
Figure 4-28 Dose distribution of treatment plan 36. a) 
Dose color-wash of the dose distribution obtained from 
hierarchical and Eclipse treatment planning systems. b) 
Dose-volume histogram of the structures in the 
optimization. 
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Figure 4-29 Dose distribution of prostate treatment plan 
37. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems. b) Dose-volume histogram of the structures in 
the optimization. 
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Figure 4-30 Dose distribution of prostate treatment plan 
38. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems.  b) Dose-volume histogram of the structures in 
the optimization. 
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Figure 4-31 Dose distribution of prostate treatment plan 
39. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems. b) Dose-volume histogram of the structures in 
the optimization. 
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Figure 4-32 Dose distribution of prostate treatment plan 
40. a) Dose color-wash of the dose distribution obtained 
from hierarchical and Eclipse treatment planning 
systems.  b) Dose-volume histogram of the structures in 
the optimization. 
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Table 4-9 D99 and D05 of the target structure from the hierarchical and Eclipse treatment planning 
systems in percentage of the prescription dose. The prescription dose was 72Gy. The average ratio of D99 
and D05 was approximately 1, suggesting that both systems produced almost the same target coverage. 
Plan 
Number 
Target D99 
of 
Hierarchical 
Plans in % 
(a) 
Target 
D99 of 
Eclipse 
Plans in 
%  (b) 
Ratio 
a/b 
Target 
D05 of 
Hierarchic
al Plans in 
% (c) 
Target 
D05 of 
Eclipse 
Plans in % 
(d) 
Ratio  
c/d 
12 97.59 98.13 0.99 103.81 106.5 0.97 
13 97.51 96.77 1 104.7 104.4 1 
15 97.83 97.83 1 103.6 103.45 1 
16 98.16 98.16 1 103.35 105.28 0.98 
18 97.9 86.78 1.12 104.22 111.81 0.93 
19 98.46 97.16 1.01 102.96 106.78 0.96 
20 97.68 97.68 1 104.13 103.84 1 
21 97.3 97.3 1 103.71 103.84 0.99 
22 97.9 98.75 0.99 103.46 103.36 1 
24 97.27 97.27 1 103.76 106.31 0.97 
26 97.66 97.66 1 103.82 104 0.99 
27 97.42 88.34 1.10 104.68 107.24 0.97 
28 98.34 98.34 1 103.08 104.44 0.98 
29 98.27 97.09 1.01 103.31 104.29 0.99 
30 97.55 99.18 0.98 104.05 105.51 0.98 
31 98.42 97.98 1 102.79 103.52 0.99 
32 97.51 99 0.98 104.15 102.81 1.01 
33 97.54 98.27 0.99 103.9 103.9 1 
34 98.38 98.38 1 103.33 104.83 0.98 
35 97.41 98.99 0.98 104.51 102.72 1.01 
36 98.2 95.03 1.03 103.33 103.66 0.99 
37 98.61 98.83 0.99 102.97 102.97 1 
38 97.96 97.96 1 104.08 104.67 0.99 
39 98.12 99 0.99 102.99 103.23 0.99 
40 97.65 98.86 0.98 104.38 103.58 1 
Average   1.01   0.99 
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Table 4-10 Maximum and minimum dose to the target structure of hierarchical and Eclipse treatment 
plans in percentage of the prescription dose. The prescription dose was 72Gy. The average ratio of the 
maximum dose was 1, suggesting that both systems produced almost the same maximum dose. The 
hierarchical plans have a higher minimum dose to target structure than that of the Eclipse plan. The higher 
minimum dose implies that the hierarchical plan didn’t produce the under dose region in the target 
structures. 
Plan 
Number 
Target 
Maximum 
Dose of 
Hierarchical 
Plans in % 
(a) 
Target 
Maximum 
Dose of 
Eclipse 
Plans in % 
(b) 
Ratio 
a/b 
Target 
Minimum Dose 
of Hierarchical 
Plans in % (c)  
Target 
Minimum 
Dose of 
Eclipse 
Plans in % 
(d) 
Ratio  
c/d 
12 105.7 108.7 0.97 85 91.9 0.92 
13 107.4 107.1 1 86.6 81.8 1.05 
15 106.4 105.3 1.01 89.9 78.9 1.13 
16 104.9 106.7 0.98 90.8 90 1 
18 105.8 113.6 0.93 86.2 61.9 1.39 
19 105.2 109.3 0.96 93 70.5 1.31 
20 106 105.3 1 89.1 79 1.12 
21 107.1 105.3 1.01 80.8 85.2 0.94 
22 108.7 104.3 1.04 86.9 94.4 0.92 
24 106.5 108.4 0.98 89.5 76.6 1.16 
26 105.9 105.9 1 89.6 86.8 1.03 
27 106.7 109 0.97 84.4 80.7 1.04 
28 105.2 106 0.99 86.6 85.2 1.01 
29 107.3 106.3 1 92 84.8 1.08 
30 107 107.8 0.99 87.6 96.8 0.90 
31 104 104.8 0.99 92.3 93.3 0.98 
32 106.9 104.6 1.02 90.5 93.1 0.97 
33 106.1 108.2 0.98 90 81.8 1.10 
34 105.7 106.2 0.99 89.2 93 0.95 
35 107.3 103.4 1.03 89.4 94 0.95 
36 106.5 105.5 1 91.5 79.4 1.15 
37 104.8 104.1 1 93.2 93.6 0.99 
38 108 106.2 1.01 91.2 90.4 1 
39 105.8 103.9 1.01 91.5 95 0.96 
118 
 
40 107.1 106 1.01 89.3 92.8 0.96 
Average   0.99   1.05 
 
Table 4-11  Rectal volume that receives at least 47Gy (V47) of the hierarchical and Eclipse treatment 
plans. The majority of hierarchical treatment plans have lower V47 than that of the Eclipse plans. 
Plan 
Number 
Rectum V47 of 
hierarchical plans 
in % (a) 
Rectum V47 of  
Eclipse plans in 
%(b) 
Ratio 
a/b 
12 47.46 48.95 0.96 
13 37.26 53.05 0.70 
15 41.74 45.88 0.90 
16 51.56 50.67 1.01 
18 47.29 55.16 0.85 
19 51.56 50.62 1.01 
20 47.64 49.8 0.95 
21 25.5 36.2 0.70 
22 31.1 44.24 0.70 
24 44.32 48.52 0.91 
26 41.76 41.2 1.01 
27 42.56 50.45 0.84 
28 39.16 48 0.81 
29 54.46 50.63 1.07 
30 55.74 70.06 0.79 
31 49.48 46.35 1.06 
32 41.91 50.76 0.82 
33 45.54 50.6 0.9 
34 44.25 47.08 0.93 
35 30.75 48.2 0.63 
36 54.69 51.87 1.05 
37 31.05 42.8 0.72 
38 35.26 42.77 0.82 
39 25.91 47.91 0.54 
40 34.2 38.37 0.89 
Average   0.87 
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Table 4-12  Maximum and minimum dose to the rectum structure of the hierarchical and Eclipse 
treatment plans in percentage of the prescription dose. The prescription dose was 72Gy. The average ratio 
of the maximum dose was 1, suggesting that both systems produced almost the same maximum dose. The 
hierarchical plans have a lower minimum dose than that of the Eclipse plans. 
Plan 
Number 
Rectum 
Maximum 
Dose of 
Hierarchical 
Plans in % 
(a) 
Rectum 
Maximum 
Dose  of 
Eclipse 
Plans in % 
(b) 
Ratio 
a/b 
Rectum 
Mean Dose 
of 
Hierarchical 
Plans in % 
(c) 
Rectum 
Mean 
Dose  of 
Eclipse 
Plans in % 
(d) 
Ratio  
c/d 
12 104.5 102.9 1.01 62.1 65 0.95 
13 104.6 102.6 1.01 54.8 69.2 0.79 
15 104.5 102.5 1.01 59.8 62.8 0.95 
16 104 102.2 1.01 66.4 65.8 1 
18 104.3 108.2 0.96 62.4 72.1 0.86 
19 103.9 103.8 1 67.5 65.1 1.03 
20 107.8 102.7 1.04 64.5 66.4 0.97 
21 104.1 103.3 1 45.9 59.8 0.76 
22 105.2 103.1 1.02 50.8 62.6 0.81 
24 104.9 103.3 1.01 59.7 61.9 0.96 
26 104.1 102 1.02 59.9 59.1 1.01 
27 104.5 104.4 1 59.8 68.1 0.87 
28 104.1 102.9 1 61.8 70.1 0.88 
29 107.3 103.4 1.03 68.6 65.9 1.04 
30 104.8 104.4 1 69.4 79.9 0.86 
31 103.9 103 1 65.2 64.3 1.01 
32 105.3 102.2 1.03 56.5 71.4 0.79 
33 107.8 102.9 1.04 58.8 69.9 0.84 
34 105.7 103 1.02 61 64 0.95 
35 105.3 102 1.03 49.9 64.3 0.77 
36 105.8 103.4 1.02 66.5 68 0.97 
37 104.2 103 1.01 50.2 60.5 0.82 
38 105.7 103 1.02 53.1 64.7 0.82 
39 104 102.6 1.01 52 67.6 0.76 
40 104 103 1 52.8 53.6 0.98 
Average   1.01   0.90 
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Table 4-13 The volume that receives at least 47Gy (V47) of the bladder of the hierarchical and Eclipse 
treatment plans. The majority of hierarchical treatment plans have lower V47 than that of the Eclipse 
plans. 
Plan 
Number 
Bladder V47 
of hierarchical 
plans in % (a) 
Bladder V47 of 
Eclipse plans in 
% (a) 
Ratio 
a/b 
12 50 51.03 0.97 
13 61.31 60.96 1 
15 27.39 32.07 0.85 
16 38.54 40.62 0.94 
18 59.34 65.31 0.90 
19 41.43 49.25 0.84 
20 37.51 41.35 0.90 
21 36.67 41.18 0.89 
22 32.15 36.47 0.88 
24 38.36 41.1 0.93 
26 47.07 52.38 0.89 
27 57.74 55.72 1.03 
28 62.21 61.58 1.01 
29 32.36 36.75 0.88 
30 27.33 34.18 0.79 
31 32.34 38.88 0.83 
32 52.09 52.76 0.98 
33 36.34 51.81 0.70 
34 18.86 18.86 1 
35 31.73 37.45 0.84 
36 35.91 38.72 0.92 
37 20.31 23.03 0.88 
38 43.33 46.47 0.93 
39 45.29 48.49 0.93 
40 36.15 39.88 0.90 
Average   0.91 
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Table 4-14 Maximum and minimum dose to the rectum structure of the hierarchical and Eclipse treatment 
plans in percentage of the prescription dose. The prescription dose was 72Gy. The average ratio of the 
maximum dose was 1, suggesting that both systems produced almost the same maximum dose. 
Hierarchical plans have a lower minimum dose than that of Eclipse plans. 
Plan 
Number 
Bladder 
Maximum 
Dose of 
Hierarchical 
Plans in % 
(a) 
Bladder 
Maximum 
Dose of 
Eclipse 
Plans in % 
(b) 
Ratio 
a/b 
Bladder 
Mean Dose 
of 
Hierarchical 
Plans in % 
(c) 
Bladder 
Eclipse 
Mean 
Dose in 
% (d) 
Ratio  
c/d 
12 105.6 106.1 0.99 58.5 60.1 0.97 
13 106.6 105.7 1 74.5 77.2 0.96 
15 104.5 105.3 0.99 39.9 48.3 0.82 
16 104.3 104.8 0.99 54.9 57.8 0.94 
18 105.5 112 0.94 74.3 82.5 0.90 
19 104.6 108.3 0.96 56.3 67.3 0.83 
20 106 105.3 1 45.4 48.3 0.93 
21 104.2 104.3 0.99 50.1 57.2 0.87 
22 104.5 104 1 39.9 44.6 0.89 
24 105.1 107.1 0.98 47.2 50 0.94 
26 105.1 104 1.01 58.9 61.8 0.95 
27 106.3 107.6 0.98 71.8 70.7 1.01 
28 103.7 105.1 0.98 76.3 79.3 0.96 
29 104.4 104.8 0.99 41.6 47 0.88 
30 105 106.6 0.98 34.8 40.5 0.85 
31 104 104.2 0.99 43.3 47.6 0.90 
32 105.1 104 1.01 61.9 64 0.96 
33 104.4 105.1 0.99 48.1 58.2 0.82 
34 104.7 105.8 0.98 27.9 28.3 0.98 
35 107.1 103.2 1.03 42.6 47.1 0.90 
36 106.5 105.1 1.01 43.8 46.8 0.93 
37 102.8 103.8 0.99 25.3 27.6 0.91 
38 106.4 104.4 1.01 53 55.9 0.94 
39 103.5 103.6 0.99 57.7 64.5 0.89 
40 105.6 104.7 1.0 46.2 49.3 0.93 
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Table 4-15 Maximum and average femur dose of the hierarchical and Eclipse treatment plans in 
percentage of the prescription dose. The prescription dose was 72Gy. The average ratio of the 
maximum dose was 1, suggesting that both systems produced almost the same maximum dose. 
Hierarchical plans have a higher minimum dose to femur than that of Eclipse plans. 
Plan 
Number 
Femur 
Maximum 
Dose of 
Hierarchical 
Plans in % (a) 
Femur 
Maximum 
Dose  of 
Eclipse 
Plans in % 
(b) 
Ratio 
a/b 
Femur Mean 
Dose of 
Hierarchical 
Plans in % 
(c) 
Femur Mean 
Dose of 
Eclipse 
Plans in % 
(d) 
Ratio  
c/d 
12 65.6 75.7 0.86 15 14.8 1.01 
13 82.4 80.2 1.02 27.7 26.4 1.04 
15 62.7 55.5 1.12 19.3 16.5 1.16 
16 64.6 66.4 0.97 15 13.1 1.14 
18 72.7 83.5 0.87 19.1 17 1.12 
19 81.4 67.8 1.20 25.1 22.4 1.12 
20 81.7 70.6 1.15 27 24.6 1.09 
21 89.4 62.7 1.42 34.1 20.4 1.67 
22 76.4 71.4 1.07 20.3 18.2 1.11 
24 75.8 77 0.98 24.3 22.7 1.07 
26 68.5 72.2 0.94 16.9 16.6 1.01 
27 84.4 87.6 0.96 28.3 23.2 1.21 
28 85.6 85.1 1.0 19.7 18.2 1.08 
29 56.7 58.9 0.96 16.9 15 1.12 
30 94.2 90.7 1.03 24.2 21.1 1.14 
31 63.8 62.8 1.01 13.2 12.7 1.03 
32 75.4 75.2 1.0 16.7 15.1 1.10 
33 75.6 72.5 1.04 22.4 18.4 1.21 
34 56.6 60.6 0.93 14 14.2 0.98 
35 66.1 67.9 0.97 20 19.4 1.03 
36 63.9 71.8 0.88 23.2 22.5 1.03 
37 51.9 50.1 1.03 12.9 11.6 1.11 
38 70.2 61 1.15 24.5 19.7 1.24 
39 58.1 41.8 1.38 20.8 17.7 1.17 
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40 83.2 78.7 1.05 28.1 26.4 1.06 
Average   1.04   1.12 
 
4.5.1 Deliverability of the Treatment plans 
The linear accelerator can’t deliver the beam profile with a large monitor unit (MU). We found 
that the smaller value of the Laplacian function corresponded to the smooth beam profile and 
lower MU. Therefore, we minimized the Laplacian function in the fifth step of optimization to 
smooth the beam profile (Figure 4-33 and Figure 4-35). The hierarchical method produced a 
smaller MU in some treatment plans and a larger one in others. Table 4-16 shows the ratio 
between the MU of the hierarchical and Eclipse systems. The average MU ratio was 1.27, 
suggesting that the MU of the hierarchical system was larger than that of the Eclipse system. 
Although MU of the hierarchical system was larger than that of the Eclipse system, it was still 
within a reasonable range. Therefore, the hierarchical system did not substantially compromise 
the deliverability of the treatment plans. 
Table 4-16 Monitor unit of the beam profile of treatment plans prepared using the hierarchical and Eclipse 
treatment planning systems. 
Plan 
Number 
Monitor Unit of 
Hierarchical Plans (a) 
Monitor Unit of 
Eclipse Plans(b) 
Ratio 
a/b 
12 1189 1121 1.06 
13 1307 1063 1.23 
15 1176 958 1.23 
16 1211 1002 1.21 
18 1247 1290 0.97 
19 1075 1101 0.98 
20 1716 1235 1.39 
21 1516 869 1.74 
22 1123 823 1.36 
24 1257 1394 0.90 
26 1145 875 1.31 
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27 1278 1199 1.07 
28 1587 1575 1.01 
29 1181 1022 1.16 
30 1457 941 1.55 
31 1102 974 1.13 
32 1142 919 1.24 
33 1244 916 1.36 
34 1132 938 1.21 
35 1206 793 1.52 
36 1131 861 1.31 
37 1160 755 1.54 
38 1210 805 1.50 
39 1333 693 1.92 
40 1265 979 1.29 
Average   1.28 
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a) Beam profile of posterior-anterior beam 
 
b) Beam profile of right anterior oblique beam 
Figure 4-33 Beam profile of treatment plan 5 prepared using the hierarchical system. 
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a) Beam profile of posterior-anterior beam 
 
b) Beam profile of right anterior oblique beam 
Figure 4-34 Beam profile of treatment plan 6 prepared using the hierarchical system. 
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a) Beam profile of posterior-anterior beam 
  
b) Beam profile of right anterior oblique beam 
Figure 4-35 Beam profile of treatment plan 8 prepared using the hierarchical system. 
4.6 Discussion and Conclusion 
Our findings demonstrate that treatment plans could be automatically produced without trial-and-
error iterations. We compared the treatment plans of 31 prostate patients prepared using the 
hierarchal system with that prepared by the planner using the Eclipse treatment planning system. 
The result showed that the hierarchical system produced better treatment plans in the majority of 
cases. The hierarchical system reduced the mean dose to the bladder and rectum by 10%, on 
average, while the dose to 95% of the target structure was the same from both systems. 
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Similarly, the dose to target was homogenous from the hierarchical system than from that of the 
Eclipse system in the majority of the treatment plans. 
Different methods have been proposed to automate treatment planning. One such method is 
maintaining the database of the previously treated patients and selecting a patient from the 
database to prepare the plan of a new patient [111]. This method requires maintenance of a large 
database and the ability to find a previous patient that is closely related to the new patient within 
the database. Moreover, the quality of the new treatment plan depends on the quality of the old 
plan. By contrast, the hierarchical method does not depend on the old treatment plan’s quality. It 
formalizes the intuitive notion of priority that the physician prescribed while creating treatment 
plans. Therefore, the hierarchical method could produce the best, mathematically guaranteed 
treatment plans with a fixed structure priority. 
Another approach to automate the treatment planning process is exploring the Pareto surface to 
find the best Pareto optimal solution [74], [112]–[114]. The method is attractive because the 
planner can navigate different optimal solutions and evaluate the trade-off in dose distribution to 
structures. However, the computation of the whole Pareto surface is not feasible and the 
algorithm may not display all possibilities. On the other hand, the hierarchical method improves 
on each goal as much as possible. Therefore, the hierarchical method could give better visibility 
to the trade-off in dose distribution of different structures than the Pareto navigation method. 
Our observations of dose distribution in the hierarchical system are in accordance with the 
observations of other research groups. We observed that the hierarchical system produced a 
lower dose in the rectum and bladder and a higher dose in the femur. The rectum and bladder had 
higher priority in optimization than the femur. Therefore, the lower priority goal was sacrificed 
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to improve on the higher priority goals. The finding was in accordance with  Breedveld, et al. 
[69] who also needed to relax lower priority goals to improve on higher priority goals. 
One concern of the hierarchical method is that higher priority goals might dominate lower 
priority goals and there would be little room to improve on lower priority goals[43], [51]. The 
hierarchical method uses the "slip" parameter from the second through fifth steps of 
optimization. The "slip" parameter increases the size of the feasibility space and thus provides 
room for improvement in lower priority goals. The "slip" relaxes on higher priority goals while 
optimizing lower priority goals. In our optimization, we used the same value of "slip" for all 
prostate plans. This is in contrast to the lexicographic method proposed by Jee, et al. [73] where 
they relax higher priority goals, in a different extent, while optimizing lower priority goals. 
Future work in hierarchical optimization could focus on studying the behavior of the optimal 
solution with larger "slip" on the higher priority goal.  
In summary, the hierarchical method could be used to automate the treatment planning process in 
a clinical setting. The treatment plans produced by the hierarchical method were better than those 
produced by the planner in the majority of cases. The automatically produced treatment plans 
have uniform dose in the target structure and lower dose in the rectum and bladder while having 
the same target coverage. The automation of treatment planning has the potential to change the 
quality of radiation therapy treatment planning. The method could explore the solution space that 
a planner cannot explore using the trial-and-error method and thus could produce better 
treatment plans. Moreover, the method could open the door for adaptive radiation therapy, which 
requires automatic re-planning to incorporate changes inpatient geometry while treating the 
patient.   
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Chapter 5: Conclusion 
 
This dissertation investigates hierarchical optimization to automate the Intensity Modulated 
Radiation Therapy (IMRT) treatment planning process. The state-of-the-art treatment planning 
application requires trial-and-error iterations to produce clinically acceptable treatment plans. 
The planner cannot produce the best dose distribution by using the trial-and-error iterations 
because there is no way to determine the exact sequence of iterations that will lead to the best 
dose distribution. Hierarchical optimization has the potential to shift the treatment planning 
paradigm from a trial-and-error manual process to an ideal automated process. The hierarchical- 
based treatment planning application could probe a larger search space than that probed by 
planners using trial-and-error iterations. Therefore, the hierarchical system produces better 
treatment plans than those produced by planners using the trial and error method. Better 
treatment plans will ultimately improve the quality of radiation therapy treatment.  
Hierarchical optimization uses large-scale, nonlinear, constrained optimization formulation to 
automate the treatment planning process. This type of large-scale, nonlinear optimization is 
computationally intensive and slower than the traditional IMRT optimization problem. 
Moreover, the mathematical model proposed in previous studies has not been used to prepare 
treatment plans in a clinical setting. Therefore, this dissertation addresses three issues of 
hierarchical optimization: 1) voxel sampling to reduce optimization time was explored, 2) the 
open source optimization solver was customized to solve the large-scale, nonlinear, constrained 
hierarchical optimization problem, 3) the mathematical model was formulated to prepare 
treatment plans automatically.  
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Hierarchical optimization has thousands of variables and millions of constraints in it. The 
optimization solver takes substantial time to solve a large-scale, constrained optimization 
problem. Therefore, we proposed a voxel sampling algorithm to reduce optimization time. The 
algorithm categorizes the voxel of a structure into the boundary and interior voxels. A voxel is 
called a boundary voxel if there is no voxel in at least one of four directions. Similarly, a voxel is 
called an interior voxel if voxels surround it in all directions. Dose to boundary voxels are 
difficult to optimize because the dose starts to change from the boundary voxel of a structure. 
Therefore, the sampling algorithm includes all boundary voxels of a structure and samples the 
interior voxels using the K-mean clustering algorithm. Hierarchical optimization was run on the 
sampled voxels to prepare the treatment plans. We found that the sampling sped up the 
optimization by 2-3 times without sacrificing the quality of the treatment plans. The average 
dosimetric error occurred when the sampling was less than 1%. Therefore, the boundary and 
interior voxel sampling is an attractive method to reduce optimization time without 
compromising the quality of the dose distribution. 
The previous study solved the hierarchical optimization formulation using the Mosek solver. 
Mosek solver has two problems: 1) it cannot solve the nonlinear, constrained optimization 
problem, 2) it takes substantial time to solve the hierarchical optimization problem. The Mosek 
solver cannot be customized because it is a commercial solver and doesn’t provide access to the 
source code. Therefore, we customized an open source Interior Point Optimization solver to 
solve the large-scale, constrained optimization problem. 
The Interior Point Optimization Solver (IPOPT) is an open source solver that can solve the linear 
and nonlinear, convex, and non-convex, large-scale optimization problem. The solver is written 
in C++ and uses the Interior Point Algorithm to solve the constrained optimization problem. The 
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hierarchical optimization module was developed in C++ and uses the IPOPT functions to solve 
the optimization problem. The optimization module is integrated with CERR (Computational 
Environment for Radiotherapy Research), a widely used software platform for developing and 
sharing radiation therapy treatment planning research, and thus provides the complete suite of the 
treatment planning application.  
The hierarchical optimization module was sped up by optimizing the memory access of the large 
sparse matrix. The CERR application precomputes the dose to each structure and stores it in the 
sparse matrix called the "influence matrix." The hierarchical optimization repeatedly accesses the 
influence matrix to compute the dose for each structure. We studied the memory access pattern 
of the influence matrix and modified the code to reduce memory latency in accessing the 
influence matrix. We solved the hierarchical optimization formulation proposed by Clark, et 
al.[88] by using the IPOPT solver and compared the run time and dose quality of the IPOPT and 
Mosek-based applications. The dose distribution of the treatment plans were exactly the same, 
but the IPOPT-based application was almost 15-65 times faster than the Mosek-based 
application.   
It’s essential to prepare treatment plans in a clinical setting using hierarchical optimization to 
demonstrate its viability. Therefore, we trained the hierarchical optimization model in six 
prostate plans to formulate the optimization model and automatically prepared 25 prostate plans. 
The treatment plans were prepared using the same clinical criteria used by the planner to prepare 
treatment plans at Memorial Sloan Kettering Cancer Center. We found that the nonlinear, 
constrained optimization model is needed to prepare treatment plans automatically. The dose 
distribution of the majority of automatically prepared plans was better than that prepared by a 
planner using the Eclipse treatment planning system. 
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Future studies of hierarchical optimization could focus on preparing the treatment plans of head 
and neck, lung and other types of cancer. It’s essential to demonstrate that hierarchical 
optimization is broad enough to produce automatic treatment plans for different types of cancer. 
The formulation of prostate plans could be extended to demonstrate that treatment plans can be 
automatically generated for different types of cancer. 
The hierarchical optimization problem is computationally intensive because of the thousands of 
variables and millions of constraints in it. The computational time of hierarchical optimization 
could be reduced by using parallel computation. The optimization performs the substantial 
matrix operations in each iteration to find the optimal solution. The matrix operations could be 
performed in graphics processing units (GPUs) to reduce hierarchical optimization time. 
Uncertainty arises in treatment planning due to the motion of structures and differences in patient 
setup during multiple treatments of the patient. Effectiveness of treatment plans is diminished 
due to these uncertainties. Treatment planning should incorporate uncertainties into the 
optimization to produce robust treatment plans. The robust plan incorporates uncertainties during 
optimization and therefore is less sensitive to the changes that come during treatment plan 
delivery. Hierarchical optimization can easily be extended to incorporate robustness in treatment 
planning. A new step can be added to handle the robustness in hierarchical optimization. The 
ability to prepare a robust, automatic plan will improve the quality of radiation therapy treatment 
plans.  
In conclusion, this dissertation demonstrated that treatment plans could be prepared 
automatically without manual intervention. Automatic treatment planning shifts the paradigm of 
radiation therapy from manual trial and error to an ideal automated process. The elimination of 
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trial and error iterations will improve patient care quality of because treatment planning will no 
longer depend on planner expertise. The automated system will open the door for adaptive 
radiation therapy as treatment plans can be automatically re-planned in real time to adapt to 
changes in patient geometry. 
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